{"study_id": 105042, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of alanine in the context of DPP-4 activity and its implications for diabetes and cardiovascular health.", "results_summary": "The study found that DPP-4, which cleaves peptides containing alanine, plays a role in inflammatory signaling, vascular smooth cell proliferation, and oxidative stress. DPP-4 inhibitors showed potential cardiovascular protective effects in preclinical studies but not in high-risk type 2 diabetes patients in clinical trials.", "population_specificity": "High-risk patients with type 2 diabetes (in clinical trials); various cells and in vivo models (in preclinical studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.437327+00:00"}
{"study_id": 105041, "supplement_id": 863, "safety_score": "60", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of GS-5806, an oral RSV-entry inhibitor, in reducing viral load and clinical disease severity in healthy adults challenged with RSV.", "results_summary": "GS-5806 significantly reduced viral load, mucus weight, and symptom scores compared to placebo. Adverse events, including increased alanine aminotransferase levels, were more common in the treatment group.", "population_specificity": "Healthy adults inoculated with RSV.", "effective_dosage": "Various doses: 50 mg initial + 25 mg daily (4 days), 50 mg initial + 25 mg daily (2 days), 100 mg single dose, 10 mg initial + 5 mg daily (4 days).", "study_duration": "5 days (variable by cohort).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.440495+00:00"}
{"study_id": 105043, "supplement_id": 863, "safety_score": "40", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the long-term efficacy and safety of deferasirox (DFX) in children with sickle cell disease, including monitoring alanine aminotransferase (ALT) as a safety marker.", "results_summary": "The study found that 53% of patients experienced reversible transaminitis episodes, likely due to drug-induced hepatitis, indicating potential liver safety concerns related to ALT levels. Additionally, more than 50% of children had inadequate control of iron overload with DFX, suggesting limited efficacy.", "population_specificity": "62 regularly transfused children with sickle cell disease (mean age 9.2 \u00b1 3.2 years) managed in the East London and Essex Clinical Haemoglobinopathy Network.", "effective_dosage": "Mean dose at 36 months was 25 mg/kg/day.", "study_duration": "Mean duration of DFX treatment was 2.5 \u00b1 1.4 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:31.532204+00:00"}
{"study_id": 105044, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether serum HBV RNA levels could predict HBeAg seroconversion during polymerase inhibitor treatment in chronic HBV patients.", "results_summary": "The study found that a stronger decline in HBV RNA levels at months 3 and 6 of treatment was the strongest predictor of HBeAg seroconversion compared to other markers like HBV DNA, HBsAg, and alanine aminotransferase. No direct effects of alanine were assessed.", "population_specificity": "62 patients with chronic HBV infection (50 HBeAg positive).", "effective_dosage": "Not specified", "study_duration": "Mean duration of 30 \u00b1 15 months (range, 4-64 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:32.597190+00:00"}
{"study_id": 105046, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of methazolamide, not alanine, as a potential therapy for type 2 diabetes.", "results_summary": "Methazolamide treatment resulted in a modest reduction in HbA1c (-0.39%), increased the proportion of patients achieving HbA1c \u22646.5%, reduced alanine aminotransferase levels (~10 units/L), and led to weight loss (2%) in metformin-cotreated patients.", "population_specificity": "76 patients with type 2 diabetes.", "effective_dosage": "40 mg twice daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.487316+00:00"}
{"study_id": 105045, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of two levofloxacin dosing regimens (750 mg for 5 days vs. 500 mg for 7-14 days IV) for treating community-acquired pneumonia, including assessing alanine aminotransferase elevation as a lab abnormality.", "results_summary": "The study found that levofloxacin 750 mg for 5 days was non-inferior in efficacy to 500 mg for 7-14 days, with similar bacterial eradication rates (100%) and comparable adverse drug reactions, including mild alanine aminotransferase elevation. Most adverse effects were mild and well-tolerated.", "population_specificity": "Chinese and broader Asian population with community-acquired pneumonia.", "effective_dosage": "750 mg IV once daily for 5 days or 500 mg IV once daily for 7-14 days.", "study_duration": "Median treatment duration was 5.0 days (750 mg group) and 9.0 days (500 mg group).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.785123+00:00"}
{"study_id": 105039, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and tolerability of ezetimibe+fenofibrate versus pravastatin monotherapy in dyslipidemic HIV-positive patients on protease inhibitors, not specifically focused on Alanine.", "results_summary": "The study found that ezetimibe+fenofibrate improved lipid profiles more effectively than pravastatin, but Alanine aminotransferase levels remained unchanged in both groups, indicating no significant impact on Alanine-related outcomes.", "population_specificity": "Dyslipidemic HIV-positive patients on stable protease inhibitor therapy.", "effective_dosage": "Not applicable (study did not focus on Alanine dosage).", "study_duration": "Six months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:37.076175+00:00"}
{"study_id": 105048, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to develop a noninvasive scoring system (PLALA score) using platelet count, serum albumin, and aminotransferase/alanine aminotransferase ratio (AAR) to predict liver cirrhosis in NAFLD patients.", "results_summary": "The study identified optimal cutoff values for platelet count, serum albumin, and AAR, combining them into an unweighted PLALA score. A PLALA score \u2265 2 demonstrated sufficient accuracy for detecting liver cirrhosis in NAFLD patients.", "population_specificity": "1,048 patients with liver-biopsy-confirmed NAFLD from nine hepatology centers in Japan.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:39.503808+00:00"}
{"study_id": 105049, "supplement_id": 863, "safety_score": "20", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of telcagepant, a CGRP receptor antagonist, for migraine prevention, with a focus on its impact on alanine aminotransferase (ALT) levels.", "results_summary": "Telcagepant showed efficacy in reducing monthly headache and migraine days compared to placebo, but significant hepatotoxicity (elevated ALT and aspartate aminotransferase levels) was observed, leading to trial termination. The study suggests potential for CGRP receptor antagonism in migraine prophylaxis but highlights safety concerns with daily telcagepant use.", "population_specificity": "Patients experiencing 3-14 migraine days during a 4-week baseline.", "effective_dosage": "140 mg or 280 mg twice daily.", "study_duration": "Mean treatment duration was 48-50 days (planned for 12 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:40.335182+00:00"}
{"study_id": 105050, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to examine the effect of different amounts and forms of dietary fructose on liver health, including alanine aminotransferase (ALT) levels, in humans.", "results_summary": "The study found insufficient evidence to draw conclusions about the effects of fructose, HFCS, or sucrose on NAFLD, including alanine aminotransferase (ALT) levels, due to confounding factors like excessive energy intake.", "population_specificity": "Adults without NAFLD (predominantly healthy, young men) and a small subset of adults or children with NAFLD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:40.602611+00:00"}
{"study_id": 105051, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the clinical presentation and severity of liver disease in children with hepatitis D virus (HDV) infection versus hepatitis B virus (HBV) monoinfection.", "results_summary": "The study found that children with HDV infection had more severe liver disease, including higher rates of cirrhosis, splenomegaly, and abnormal liver enzyme levels, compared to those with HBV monoinfection. No significant differences in liver disease severity were observed based on HBeAg status in HDV patients.", "population_specificity": "Pediatric patients (age \u226418 years) with chronic HDV infection or HBV monoinfection in Pakistan.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:41.310011+00:00"}
{"study_id": 105052, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to determine whether newly proposed hepatotoxicity biomarkers would rise alongside ALT elevations during cholestyramine treatment, which is not associated with serious liver injury.", "results_summary": "Cholestyramine treatment caused ALT elevations (>3x ULN) in 11 of 67 subjects, accompanied by significant increases in liver-derived biomarkers (miR-122, sorbitol dehydrogenase, cytokeratin 18, HMGB1, and glutamate dehydrogenase), indicating hepatocyte necrosis and apoptosis despite no clinical liver safety concerns.", "population_specificity": "Healthy adult volunteers", "effective_dosage": "8g daily", "study_duration": "11 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.311232+00:00"}
{"study_id": 105057, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it assesses the effectiveness and safety of statins in children with familial hypercholesterolemia.", "results_summary": "The study does not report specific findings related to Alanine.", "population_specificity": "Children with familial hypercholesterolemia (aged 7 to 17 years).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.842220+00:00"}
{"study_id": 105053, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the clinical effect and safety of hepatectomy combined with 'Jianpi Huayu Therapy' (which includes Alanine) in treating hepatocellular carcinoma (HCC).", "results_summary": "The study found that combining hepatectomy with 'Jianpi Huayu Therapy' improved disease-free survival (DFS) and overall survival (OS), reduced post-operative recurrence, and lowered Alanine aminotransferase (ALT) levels compared to hepatectomy alone.", "population_specificity": "120 patients with hepatocellular carcinoma (HCC).", "effective_dosage": "Not specified", "study_duration": "Follow-up included 1-, 3-, and 5-year survival rates, with median survival times reported.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.959624+00:00"}
{"study_id": 105047, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the efficacy and safety of the FOLFIRINOX chemotherapy regimen in Japanese patients with metastatic pancreatic cancer, not specifically evaluating Alanine.", "results_summary": "The study found that FOLFIRINOX showed a response rate of 38.9%, median overall survival of 10.7 months, and progression-free survival of 5.6 months, with notable toxicities including neutropenia and febrile neutropenia. Elevated alanine aminotransferase levels were reported in 8.3% of patients, but the study did not focus on Alanine's effects.", "population_specificity": "Chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer.", "effective_dosage": "Not applicable (study did not evaluate Alanine).", "study_duration": "Median of eight treatment cycles (range 1-25), administered every 2 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.628878+00:00"}
{"study_id": 105055, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "To determine the relationship between host immunity and viral infection characteristics or nucleoside analogues (NAs) in chronic hepatitis B (CHB) patients receiving NA therapy, including alanine aminotransferase normalization.", "results_summary": "Both telbivudine and lamivudine significantly inhibited HBV replication and normalized alanine aminotransferase levels by 48 weeks. The therapies also reduced frequencies of PD-1+ CD8 T cells and Treg cells, correlating with declining HBV DNA and HBeAg levels, and partially restored CD8 T cell cytokine secretion.", "population_specificity": "Fifty-two HBeAg-positive CHB patients.", "effective_dosage": "Telbivudine (600 mg/d) or lamivudine (100 mg/d).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.675212+00:00"}
{"study_id": 105056, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of fasting and postprandial total bile acids (including alanine aminotransferase levels) in predicting adverse perinatal outcomes in intrahepatic cholestasis of pregnancy (ICP).", "results_summary": "The study found that fasting and postprandial total bile acids were positively correlated with serum alanine aminotransferase levels, and postprandial TBA was associated with asphyxia in ICP patients. Gestational age at diagnosis and fasting TBA were also linked to adverse perinatal outcomes.", "population_specificity": "111 patients (57 with ICP and 54 controls) evaluated for preterm birth, meconium-stained amnion, neonatal intensive-care unit admission, and asphyxia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:49.750820+00:00"}
{"study_id": 105058, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the course of alanine aminotransferase (ALT) elevation in healthy subjects administered 4 g/day of acetaminophen for at least 16 days.", "results_summary": "Most subjects (77%) had no ALT elevation or transient elevations that resolved by day 16. Among those with ALT elevations at day 16, 47/48 resolved by day 40, with no evidence of liver dysfunction.", "population_specificity": "Healthy volunteers with normal liver enzymes.", "effective_dosage": "4 g/day of acetaminophen.", "study_duration": "Minimum 16 days, up to 40 days for subjects with unresolved ALT elevations.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:50.780341+00:00"}
{"study_id": 105054, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 92, "study_goal": "The researchers aimed to assess the safety and efficacy of an all-oral, interferon-free, and ribavirin-free treatment (daclatasvir plus asunaprevir) for chronic HCV genotype 1b infection, including its effects on alanine aminotransferase levels.", "results_summary": "The study found that daclatasvir plus asunaprevir achieved high sustained virological response rates (82-90%) across different patient groups, with reversible increases in alanine aminotransferase being the most common adverse event leading to discontinuation (3% in treatment-naive patients). The treatment was well-tolerated, with low incidences of serious adverse events and grade 3-4 laboratory abnormalities.", "population_specificity": "Adults with chronic HCV genotype 1b infection, including treatment-naive patients, previous non-responders, and those medically ineligible or intolerant to peginterferon alfa plus ribavirin.", "effective_dosage": "Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily.", "study_duration": "24 weeks for treatment-naive and other cohorts (12 weeks placebo-controlled phase for treatment-naive).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:51.281422+00:00"}
{"study_id": 105061, "supplement_id": 863, "safety_score": "30", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers sought to determine the efficacy and safety of mipomersen therapy in reducing ApoB-containing lipoproteins in hypercholesterolemic patients.", "results_summary": "Mipomersen therapy significantly reduced LDL-C (33.13%), non-HDL-C (31.70%), ApoB (33.27%), and Lp(a) (26.34%) but was associated with increased injection-site reactions, flu-like symptoms, and elevated transaminases.", "population_specificity": "Patients with severe hypercholesterolemia (444 participants across six randomized controlled trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.953140+00:00"}
{"study_id": 105060, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 45, "study_goal": "The researchers were documenting a case of Gianotti-Crosti syndrome (GCS) in an adult male with elevated alanine aminotransaminase levels, associated with Parvovirus B-19 and EBV coinfection.", "results_summary": "The study reported slight bilirubin and alanine aminotransaminase elevation in a 20-year-old male with GCS, but did not evaluate Alanine's effects as a supplement. The condition resolved with corticosteroids and antihistamines.", "population_specificity": "20-year-old Caucasian male with Gianotti-Crosti syndrome and elevated alanine aminotransaminase.", "effective_dosage": "Not available", "study_duration": "3 weeks (treatment duration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:55.053145+00:00"}
{"study_id": 105059, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of asunaprevir (a selective HCV NS3 protease inhibitor) combined with peginterferon alfa-2a/ribavirin (PegIFN\u03b1/RBV) in treatment-naive adults with genotype 1 or 4 chronic HCV, including monitoring alanine aminotransferase elevations.", "results_summary": "The study found that asunaprevir improved response rates (eRVR and SVR24) compared to placebo, with manageable aminotransferase elevations. Five patients had grade 4 alanine aminotransferase elevations, which resolved after discontinuation or continued dosing.", "population_specificity": "Treatment-naive adults with genotype 1 (n=213) or 4 (n=25) chronic HCV, predominantly male (64.3%), white (83.6%), and with non-CC IL28B genotypes (71.3%).", "effective_dosage": "Asunaprevir 200mg twice daily.", "study_duration": "Up to 48 weeks (with rerandomization at week 12 for responders).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.299945+00:00"}
{"study_id": 105064, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare prophylactic and preemptive lamivudine initiation in HBsAg (+) kidney transplant recipients and evaluate the safety and efficacy of novel nucleoside analogs like tenofovir and adefovir.", "results_summary": "The study found that prophylactic lamivudine initiation may reduce hepatic dysfunction, viral breakthroughs, and elevated alanine aminotransferase concentrations, though results were not statistically significant. Tenofovir and adefovir showed adequate virologic/biochemical response and comparable safety to lamivudine in resistant cases.", "population_specificity": "HBsAg (+) kidney transplant recipients (n=58).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.627921+00:00"}
{"study_id": 105063, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the prevalence, diagnosis, and treatment of non-alcoholic fatty liver disease (NAFLD), including the role of alanine aminotransferase (ALAT) as a diagnostic marker.", "results_summary": "The study found that elevated ALAT levels, along with other markers, can help diagnose NAFLD, but liver biopsy remains the gold standard. Lifestyle changes, including weight reduction, are the primary treatment for reversing NAFLD.", "population_specificity": "General population in industrialized countries, particularly those with NAFLD or risk factors for it.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.736397+00:00"}
{"study_id": 105062, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the metabolic and histological profiles of nonobese and obese NAFLD patients, focusing on factors like ALT levels, BMI, and metabolic syndrome.", "results_summary": "The study found that nonobese NAFLD patients had similar metabolic profiles and liver disease severity (steatosis, inflammation, fibrosis) as obese patients, with 53.1% of nonobese cases classified as NASH.", "population_specificity": "465 NAFLD patients in Bangladesh, including 119 nonobese (BMI <25 kg/m\u00b2) and 346 obese (BMI \u226525 kg/m\u00b2) individuals.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:58.028805+00:00"}
{"study_id": 105066, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the clinical significance of serum alanine aminotransferase (ALT) activity, its influencing factors, and updated normal ranges in various populations.", "results_summary": "The study highlights that ALT activity is influenced by metabolic, demographic, and clinical factors, including viral hepatitis, alcohol, and medications. It also suggests extremely low ALT may indicate aging or frailty in older adults, warranting further investigation.", "population_specificity": "General clinical populations, with considerations for ethnic variations and older adults.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "Viral hepatitis, alcohol consumption, and medication were noted as influencing factors.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:59.625592+00:00"}
{"study_id": 105065, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the long-term medical outcomes of children with biliary atresia (BA) after hepato-portoenterostomy (HPE) surgery, focusing on liver function and quality of life.", "results_summary": "The study found that only 1.8% of children with BA met the criteria for an \"ideal\" outcome (no chronic liver disease, normal liver function tests, and normal quality of life) 5+ years after HPE. Most had biochemical or clinical evidence of chronic liver disease, with cholangitis and fractures reported in 17% and 5.5% of cases, respectively.", "population_specificity": "Children with biliary atresia (BA) who underwent HPE surgery (median age 9.7 years, 43% male).", "effective_dosage": "Not available", "study_duration": "Long-term follow-up (5+ years after HPE).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:00.854526+00:00"}
{"study_id": 105068, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not focus on Alanine; it evaluated the effects of nintedanib on tumor vasculature, efficacy, and safety in patients with advanced colorectal cancer.", "results_summary": "The study did not report any findings related to Alanine.", "population_specificity": "Patients with advanced colorectal cancer who had failed conventional treatment.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:01.163352+00:00"}
{"study_id": 105067, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of the Chuanhu anti-gout mixture (containing Alanine) versus colchicine in treating acute gouty arthritis.", "results_summary": "The Chuanhu anti-gout mixture was non-inferior to colchicine in reducing recurrence rates of acute gouty arthritis and showed significant changes in blood uric acid, alanine aminotransferase, and other markers, though with a higher incidence of adverse events (mainly diarrhea).", "population_specificity": "Outpatient individuals with newly diagnosed acute gouty arthritis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:03.180752+00:00"}
{"study_id": 105069, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to describe the structure of the Hepatitis B Research Network (HBRN) and the baseline characteristics of adults with chronic HBV infection, including alanine aminotransferase levels.", "results_summary": "The study found that 68% of male subjects and 67% of female subjects had elevated alanine aminotransferase levels, indicating liver inflammation, but did not assess alanine's direct effects or safety.", "population_specificity": "Adults with chronic HBV infection not receiving antiviral therapy, predominantly Asian (72%), with smaller proportions of Black (15%) and White (11%) participants.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:05.665051+00:00"}
{"study_id": 105070, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to analyze the timing of referral to a transplant center in pediatric acute liver failure (PALF) and its relation to clinical characteristics and outcomes, including liver function parameters such as alanine aminotransferase (ALAT) levels.", "results_summary": "Early-referred PALF patients had significantly higher ALAT levels (4,340 U/l) compared to late-referred patients (963 U/l), indicating more acute liver injury, but differences in survival were not significant.", "population_specificity": "Pediatric patients with acute liver failure (PALF).", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective analysis)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:05.992813+00:00"}
{"study_id": 105071, "supplement_id": 863, "safety_score": "70", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to compare the risk of hepatotoxicity (specifically ALT and bilirubin elevation) in opioid injectors receiving long-term versus short-term BUP/NX treatment.", "results_summary": "The study found no significant difference in ALT elevation\u2265grade 3 or bilirubin elevations between long-term and short-term BUP/NX treatment groups, suggesting that hepatotoxic events during BUP/NX treatment are likely due to other factors like hepatitis C seroconversion.", "population_specificity": "HIV-negative opioid injectors in China and Thailand.", "effective_dosage": "Not specified in the abstract.", "study_duration": "52 weeks for long-term treatment (LT-MAT), 18 days for short-term treatment (ST-MAT).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.306431+00:00"}
{"study_id": 105072, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of deferasirox in reducing iron overload in adult allogeneic hematopoietic stem cell transplant recipients with hematologic malignancies.", "results_summary": "Deferasirox significantly reduced serum ferritin and liver iron concentration over 52 weeks, with most adverse events being mild to moderate. Two patients showed elevated alanine aminotransferase levels, which resolved.", "population_specificity": "Adult allogeneic hematopoietic stem cell transplant recipients with transfusional iron overload in hematologic malignancies.", "effective_dosage": "10 mg/kg/day", "study_duration": "52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.367866+00:00"}
{"study_id": 105074, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus, with a focus on alanine aminotransferase (ALT) levels.", "results_summary": "Telbivudine and lamivudine significantly reduced HBV DNA and HBeAg levels, with higher HBV DNA negative conversion rates in patients with abnormal ALT levels. Both drugs showed 0% intrauterine HBV infection and immunization failure rates, outperforming the HBIG group.", "population_specificity": "Pregnant women positive for HBsAg and HBeAg.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:09.833931+00:00"}
{"study_id": 105073, "supplement_id": 863, "safety_score": "40", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of albinterferon (a fusion of albumin and interferon-\u03b12b) compared to pegylated-interferon-\u03b12a in reducing HBV-DNA and serum alanine aminotransferase levels in patients with chronic hepatitis B.", "results_summary": "All treatment groups showed significant reductions in HBV-DNA and serum alanine aminotransferase levels, though one albinterferon dose was inferior to pegylated-interferon-\u03b12a. Adverse events were common (96.4-100%) and higher for albinterferon, with dose-related increases in total adverse events and decreased lung function.", "population_specificity": "Patients with chronic hepatitis B virus (HBV) infection who were e-antigen (HBeAg) positive.", "effective_dosage": "1200 \u03bcg every 4 weeks (one of four albinterferon doses/regimens tested).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:09.963150+00:00"}
{"study_id": 105075, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers were evaluating the safety and efficacy of pazopanib, alone or combined with bicalutamide, in chemotherapy-naive castration-resistant prostate cancer (CRPC) patients, with increased alanine transaminase as a noted toxicity.", "results_summary": "The study reported increased alanine transaminase as a grade 3+ toxicity, leading to a dose reduction of pazopanib. Long-term stable disease was observed in a subset of patients, but overall, the treatment showed limited efficacy.", "population_specificity": "Chemotherapy-naive castration-resistant prostate cancer (CRPC) patients.", "effective_dosage": "Pazopanib 800 mg daily (later reduced to 600 mg daily) with or without bicalutamide 50 mg daily.", "study_duration": "Varied, with some patients remaining on treatment for up to 52 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:11.881180+00:00"}
{"study_id": 105076, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine whether high-dose L-alanine-L-glutamine infusion could normalize plasma glutamine levels without increasing plasma and cerebral glutamate in patients with severe traumatic brain injury (TBI).", "results_summary": "The study found that continuous L-alanine-L-glutamine infusion significantly increased plasma and cerebral glutamine and alanine levels without elevating glutamate or causing signs of cerebral injury. The effects were sustained over a 5-day infusion period.", "population_specificity": "Patients with severe traumatic brain injury (TBI) (n=12, divided into two groups).", "effective_dosage": "0.75 g/kg/day of L-alanine-L-glutamine.", "study_duration": "24 hours (group 1) or 5 days (group 2).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:14.780798+00:00"}
{"study_id": 105078, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess the safety and efficacy of methotrexate (MTX) in children with Crohn's disease, not specifically Alanine.", "results_summary": "The study found that 15% of patients developed elevated alanine aminotransferase levels while on MTX, but only 4% discontinued treatment due to adverse effects. The focus was on MTX, not Alanine.", "population_specificity": "Pediatric patients with Crohn's disease.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Minimum 1-year follow-up.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:15.083882+00:00"}
{"study_id": 105077, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the association between the SREBP-2 rs2228314 G>C polymorphism and the risk of nonalcoholic fatty liver disease (NAFLD), including the role of alanine aminotransferase as a potential risk factor.", "results_summary": "The study found that the GG genotype and G carrier (CG+GG) of the rs2228314 G>C polymorphism in the SREBP-2 gene were strongly associated with NAFLD susceptibility. Alanine aminotransferase was identified as one of the factors potentially increasing NAFLD risk.", "population_specificity": "Han Chinese population (300 NAFLD patients and 160 healthy controls).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:15.731000+00:00"}
{"study_id": 105081, "supplement_id": 863, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of a polyherbal combination (G-400) on glycemic and lipidemic control in patients with type 2 diabetes mellitus.", "results_summary": "The study found that G-400 significantly reduced fasting and postprandial blood glucose levels, improved lipid profiles, and showed no significant toxicologic changes in enzyme activities or blood markers.", "population_specificity": "89 patients with type 2 diabetes mellitus and 50 healthy volunteers from Kerala, India.", "effective_dosage": "1000 mg/d", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.534741+00:00"}
{"study_id": 105080, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential application of HBsAg quantification in managing chronic hepatitis B (CHB) patients receiving nucleos(t)ide analog (NA) therapy, including its impact on alanine aminotransferase (ALT) normalization.", "results_summary": "The study found that NA therapy induces HBV viral suppression, normalization of ALT levels, and improvement in liver histology, though HBsAg decline is slower compared to interferon treatment. Rapid HBsAg decline during NA therapy may predict eventual HBsAg clearance.", "population_specificity": "Chronic hepatitis B (CHB) patients receiving nucleos(t)ide analog therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.936386+00:00"}
{"study_id": 105082, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to assess the effect of vitamin E supplementation on lowering alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with NAFLD, NASH, and CHC.", "results_summary": "Vitamin E supplementation optimized ALT and AST levels in patients with NASH and CHC, but the effect was not statistically significant in NAFLD patients. The strongest effects were observed in NASH patients.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and chronic hepatitis C (CHC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.230837+00:00"}
{"study_id": 105079, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of the S-1 plus trastuzumab combination regimen in HER2-positive metastatic breast cancer patients, including monitoring adverse effects such as increased serum alanine aminotransferase.", "results_summary": "The study found that the combination regimen had an overall response rate of 53.6% and a clinical benefit rate of 75.0%, with progression-free survival of 30 weeks. Adverse effects included increased serum alanine aminotransferase, leucopenia, neutropenia, and diarrhea.", "population_specificity": "HER2-positive metastatic breast cancer patients.", "effective_dosage": "S-1 (80 mg/m\u00b2/day, days 1 to 28, every 6 weeks) and trastuzumab (2 mg/kg weekly).", "study_duration": "Median of 3.5 cycles (range 1-10).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.232582+00:00"}
{"study_id": 105083, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of adjuvant vitamin E on outcomes related to alanine aminotransferase (ALT) normalization and histological improvement in pediatric NAFLD/NASH.", "results_summary": "The meta-analysis found no significant effect of adjuvant vitamin E on normalizing serum ALT levels compared to placebo. Histological improvement data were limited and showed substantial heterogeneity between studies.", "population_specificity": "Children with nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified (varied across studies).", "study_duration": "Not specified (varied across studies).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:19.803265+00:00"}
{"study_id": 105084, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of entecavir treatment in nucleos(t)ide-na\u00efve HBeAg-positive chronic hepatitis B patients over a 4-year period.", "results_summary": "The study found that entecavir treatment led to significant viral suppression, with 90% of patients achieving normal alanine aminotransferase levels by the end of the study. HBeAg loss and seroconversion rates were modest, increasing slightly over time.", "population_specificity": "Nucleos(t)ide-na\u00efve HBeAg-positive chronic hepatitis B patients.", "effective_dosage": "Not specified in the abstract.", "study_duration": "4 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:24.398218+00:00"}
{"study_id": 105085, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of two alternative intravenous lipid emulsions (SMOF and Lipofundin) on liver function in neonates, premature infants, and children with abnormal liver function tests.", "results_summary": "Both SMOF and Lipofundin improved liver function, with SMOF showing greater reductions in ALT, ALP, and \u03b3-GT levels and a higher incidence of resolving abnormal liver function tests. Hyperbilirubinaemia incidence also decreased significantly during treatment.", "population_specificity": "Neonates, premature infants, and children aged 0-16 years with abnormal liver function tests.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:24.881460+00:00"}
{"study_id": 105086, "supplement_id": 863, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy and safety of adjuvant UFT/LV (which includes leucovorin, a derivative of alanine) versus standard 5-FU/l-LV in stage III colorectal cancer patients post-D2/D3 lymph node dissection.", "results_summary": "The study found UFT/LV non-inferior to 5-FU/l-LV in disease-free survival (DFS), with a hazard ratio of 1.02. Grade 3/4 toxicities included 8.7% alanine aminotransferase elevation in the UFT/LV group, but no treatment-related deaths were reported.", "population_specificity": "Stage III colorectal cancer patients who underwent Japanese D2/D3 lymph node dissection (median age 61 years).", "effective_dosage": "UFT 300 mg/m\u00b2/day and LV 75 mg/day for 28 days every 5 weeks (5 courses).", "study_duration": "Five courses administered over approximately 25 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.654446+00:00"}
{"study_id": 105087, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the safety profile and management of toxicities of bosutinib versus imatinib in adults with newly diagnosed chronic phase chronic myeloid leukemia (CP CML).", "results_summary": "The study found that bosutinib had higher rates of gastrointestinal events and aminotransferase elevations compared to imatinib but lower rates of edema, musculoskeletal events, and hematologic toxicities. Adverse events were manageable with dose modification and concomitant medication.", "population_specificity": "Adults with newly diagnosed (\u22646 months) chronic phase chronic myeloid leukemia (CP CML).", "effective_dosage": "Bosutinib 500 mg/d or imatinib 400 mg/d.", "study_duration": ">30 months from accrual completion.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:26.307786+00:00"}
{"study_id": 105089, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the incidence and factors associated with alanine aminotransferase (ALT) abnormalities in chronic hepatitis C patients achieving sustained virologic response after combination therapy.", "results_summary": "The study found that 28.1% of patients with sustained virologic response had abnormal ALT levels at the end of treatment, significantly associated with pegylated interferon alfa-2a, baseline fatty liver, and cirrhosis. PEG-IFN-alfa-2a-related ALT elevation normalized post-treatment, while fatty liver and cirrhosis-related elevations persisted.", "population_specificity": "700 na\u00efve chronic hepatitis C patients treated between 2003 and 2010.", "effective_dosage": "Not specified", "study_duration": "Treatment duration not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:27.643370+00:00"}
{"study_id": 105091, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether increasing the dosage of Entecavir (ETV) from 0.5 mg to 1 mg daily improved viral suppression in patients with chronic hepatitis B (CHB) who partially responded to initial treatment.", "results_summary": "The study found that increasing the ETV dose to 1 mg daily resulted in more effective suppression of HBV-DNA compared to the 0.5 mg dose, though both groups had similar rates of HBeAg loss and ALT normalization after 4 years.", "population_specificity": "HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB).", "effective_dosage": "0.5 mg and 1 mg ETV daily.", "study_duration": "4 years (1 year initial treatment, followed by 3 years of randomized dosing).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:29.032015+00:00"}
{"study_id": 105088, "supplement_id": 863, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to assess the impact of L-alanine (ALA) supplementation on endurance performance and physiological parameters during prolonged cycling.", "results_summary": "ALA possibly harmed performance compared to placebo, but it lowered heart rate during cycling and showed no significant adverse effects. The study did not find evidence that ALA enhances endurance performance.", "population_specificity": "Eight male cyclists (age 22.3 \u00b1 5.6 years, weight 70.0 \u00b1 8.0 kg, VO2max 59.4 \u00b1 4.9 ml/kg/min).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Single session (120 min constant-load cycling + 30-km time trial).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:29.421503+00:00"}
{"study_id": 105090, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the maximum-tolerated dose (MTD) and recommended dose (RD) of gemcitabine with concurrent radiotherapy in patients with muscle-invasive bladder cancer, including assessing toxicity profiles.", "results_summary": "The study found that gemcitabine with radiotherapy was well tolerated, with the MTD at 50 mg/m\u00b2 and RD at 40 mg/m\u00b2 twice weekly. Late toxicity was rare and low-grade, with a 2-year locoregional failure rate of 32%.", "population_specificity": "Patients with urothelial cancer (cT2-T4, cN0-1, M0) ineligible for surgery or cisplatin or refusing organ loss.", "effective_dosage": "20, 27, 30, 33, 50, and 40 mg/m\u00b2 twice weekly (dose levels 1-6).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:29.882263+00:00"}
{"study_id": 105094, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of alanine in metabolic pathways related to lactate metabolism, exercise physiology, and diseases like diabetes and cancer.", "results_summary": "The abstract highlights that alanine, along with glucose, produces pyruvate, which is involved in lactate metabolism and energy production, but does not specifically report on alanine's direct effects or outcomes.", "population_specificity": "Not specified (general metabolic pathways discussed, with mentions of obese individuals, diabetes patients, and cancer cases).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.412434+00:00"}
{"study_id": 105093, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the risk of fatigue and hepatic adverse events (including elevated alanine aminotransferase, ALT) associated with lapatinib use in solid tumor patients.", "results_summary": "The meta-analysis found no statistically significant increased risk of elevated ALT or other hepatic adverse events with lapatinib compared to control treatments. The evidence for hepatotoxicity or fatigue risks was not fully convincing.", "population_specificity": "Patients with solid tumors participating in randomized Phase II and III clinical trials.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.797391+00:00"}
{"study_id": 105092, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to assess the safety and efficacy of losmapimod, a p38 MAPK inhibitor, in reducing inflammatory markers and cardiac events in NSTEMI patients, with a focus on alanine aminotransferase (ALT) concentrations as a safety measure.", "results_summary": "The study found no significant differences in safety outcomes, including ALT concentrations, between losmapimod and placebo groups. Losmapimod reduced hsCRP at 72 hours and BNP at 12 weeks but did not affect troponin I AUC.", "population_specificity": "Patients with non-ST-segment elevation myocardial infarction (NSTEMI).", "effective_dosage": "7.5 mg or 15.0 mg loading dose followed by 7.5 mg twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.058807+00:00"}
{"study_id": 105095, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers were evaluating the efficacy and safety of nalmefene in reducing alcohol consumption and related biomarkers, including alanine aminotransferase, in alcohol-dependent patients.", "results_summary": "The study found that nalmefene significantly reduced total alcohol consumption, heavy drinking days, and improved secondary outcomes like alanine aminotransferase levels. It was generally well tolerated with limited contraindications.", "population_specificity": "Alcohol-dependent patients with high or very high drinking risk levels.", "effective_dosage": "As-needed dosage (specific amount not detailed).", "study_duration": "6 months.", "interactions": "Limited interactions mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:35.230569+00:00"}
{"study_id": 105096, "supplement_id": 863, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of switching from long-term entecavir to peginterferon alfa-2a in achieving HBeAg seroconversion and HBsAg loss in chronic hepatitis B patients.", "results_summary": "Switching to peginterferon alfa-2a resulted in higher HBeAg seroconversion rates (14.9% vs. 6.1%) and HBsAg loss (8.5%) compared to continuing entecavir. Early on-treatment HBsAg decline predicted better response, with the highest rates in patients with week 12 HBsAg <200 IU/ml.", "population_specificity": "HBeAg-positive chronic hepatitis B patients with virological suppression after 9-36 months of entecavir therapy.", "effective_dosage": "Peginterferon alfa-2a 180 \u03bcg/week or entecavir 0.5mg/day.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:37.610834+00:00"}
{"study_id": 105099, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine how haemolysis caused by pneumatic tube transportation affects alanine aminotransferase (ALT) assay results.", "results_summary": "The study found that haemolysis (HI > 20) was more common in tube-transported plasma samples (17.5%) than hand-delivered samples (2.6%), potentially interfering with ALT measurements. The median HI in tube-transported plasma was 85, indicating significant haemolysis.", "population_specificity": "Routine lithium heparinate plasma and serum samples from clinical laboratories.", "effective_dosage": "Not available", "study_duration": "Not applicable (single transportation event)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:38.474375+00:00"}
{"study_id": 105097, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the clinical significance of protocol liver biopsy (PLB) in pediatric liver transplantation (LT) and identify factors associated with histopathological scores, including alanine aminotransaminase (ALT) levels.", "results_summary": "The study found that ALT levels \u2265 20 IU/L at two years post-LT were associated with higher histopathological activity scores (\u2265 A1), suggesting ALT as a potential marker for portal inflammation. Immunosuppressive therapy modulation to maintain ALT below 20 IU/L was recommended, and PLB at five years was effective for detecting early reversible graft fibrosis.", "population_specificity": "Pediatric patients who underwent liver transplantation.", "effective_dosage": "Not specified", "study_duration": "Follow-up at two and five years post-transplantation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:38.785426+00:00"}
{"study_id": 105098, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 45, "study_goal": "The researchers aimed to report cases of DRESS syndrome, a severe adverse drug reaction, and highlight the role of elevated alanine aminotransferase (ALT) as a diagnostic marker.", "results_summary": "The study identified six patients with DRESS syndrome, where elevated ALT (>100 U/L) was a key diagnostic criterion. The syndrome had a mortality rate of 10%-20%, and treatment involved steroids and discontinuation of the suspect drug.", "population_specificity": "Patients with DRESS syndrome attended at Centro Medico Nacional Siglo XXI, Mexico City.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:39.265661+00:00"}
{"study_id": 105101, "supplement_id": 863, "safety_score": "80", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy and safety of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM), focusing on liver function and glucose metabolism.", "results_summary": "Sitagliptin significantly reduced hemoglobin A1c (HbA1c) levels, particularly in patients with higher baseline HbA1c, and showed a positive correlation between improvements in HbA1c and liver transaminases (AST and ALT). Liver transaminases did not change significantly during treatment.", "population_specificity": "Patients with biopsy-proven NAFLD and type 2 DM (n=44).", "effective_dosage": "50 mg/day", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.130116+00:00"}
{"study_id": 105100, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of tenofovir and entecavir in previously untreated chronic hepatitis B (CHB) patients, including effects on alanine transaminase (ALT) levels.", "results_summary": "Both tenofovir and entecavir showed comparable rates of ALT normalization, HBV-DNA suppression, and HBeAg loss, with few side effects and good tolerability. The study found no significant differences in efficacy between the two drugs.", "population_specificity": "Previously untreated HBeAg-positive and HBeAg-negative chronic hepatitis B patients from 10 centers in Istanbul, Turkey.", "effective_dosage": "Not specified", "study_duration": "Mean follow-up was 18 months for tenofovir and 20 months for entecavir.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.375720+00:00"}
{"study_id": 105103, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study examined the effect of country of origin on HBV testing and chronic HBV infection prevalence among Asian and Pacific Islanders, with a secondary focus on the association between abnormal alanine aminotransferase (ALT) levels and HBV testing outcomes.", "results_summary": "The study found that foreign-born APIs had higher odds of HBV testing and positive results compared to US-born APIs. Individuals with two or more abnormal ALT levels had significantly higher odds of being tested and testing positive for HBV.", "population_specificity": "Asian and Pacific Islanders (APIs) in a managed care setting in Hawaii.", "effective_dosage": "Not available", "study_duration": "Data collected from 2006 to 2008, with at least 12 months of follow-up before 2009.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.840828+00:00"}
{"study_id": 105102, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the therapeutic effects of autologous mesenchymal stem cell (MSC) infusion, including its impact on alanine transaminase (ALT) levels, in patients with end-stage liver disease.", "results_summary": "The study found that MSC infusion led to significant improvements in ALT levels (P = 0.029) and other liver function markers, with 54% of treated patients showing near normalization of liver enzymes. However, changes in hepatic fibrosis markers were statistically nonsignificant.", "population_specificity": "Patients with post-hepatitis C virus (HCV) end-stage liver disease.", "effective_dosage": "Not specified for alanine transaminase (ALT) specifically; MSC infusion followed G-CSF mobilization for 5 days.", "study_duration": "Follow-up assessments were conducted at 3 months post-therapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.053969+00:00"}
{"study_id": 105107, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to assess the effect of isoniazid preventive therapy (which may affect alanine transaminase levels) on tuberculosis risk in HIV-1 infected patients receiving antiretroviral therapy.", "results_summary": "The study found that isoniazid preventive therapy reduced tuberculosis incidence (HR 0.63) but led to grade 3 or 4 raised alanine transaminase concentrations in some participants (19/662 in the treatment group vs. 10/667 in the placebo group).", "population_specificity": "HIV-1 infected patients in Khayelitsha, South Africa, receiving antiretroviral therapy.", "effective_dosage": "Not specified (study focused on isoniazid preventive therapy, not alanine dosage).", "study_duration": "12 months (could be completed within 15 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:48.105287+00:00"}
{"study_id": 105106, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety profile of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), including monitoring for adverse events such as elevations in alanine aminotransferase (ALT).", "results_summary": "The study found that elevations in ALT or AST occurred in 2.7% of patients, with an adjusted incidence of 1.7 per 100 person exposure years (PEY). Gastrointestinal and skin-related events were common but mostly mild to moderate and rarely led to treatment discontinuation.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "2403 mg/day (pirfenidone).", "study_duration": "Median duration of exposure was 2.6 years (range: 1 week\u20137.7 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:48.141717+00:00"}
{"study_id": 105104, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to develop and compare a new dose calibration method for the Elekta Leksell Gamma Knife using alanine-based electron paramagnetic resonance (EPR) and to verify the accuracy of delivered doses.", "results_summary": "The new calibration method showed a +0.8% deviation from the current method, and \"end-to-end\" tests revealed average deviations of -1.7% (Gammaplan v9) and -0.9% (Gammaplan v10) between measured and calculated doses, indicating good agreement.", "population_specificity": "Not specified (phantom and machine-based study, not human subjects).", "effective_dosage": "Not specified (dose rate calibration and verification, not consumption).", "study_duration": "Not specified (single measurement and testing sessions).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:48.169437+00:00"}
{"study_id": 105105, "supplement_id": 863, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the pharmacokinetic interactions between dolutegravir and boceprevir or telaprevir, including the effect on alanine aminotransferase levels.", "results_summary": "The study found that coadministration of dolutegravir with boceprevir or telaprevir had no clinically significant effect on dolutegravir pharmacokinetics. Elevated alanine aminotransferase was reported as an adverse event in one subject.", "population_specificity": "Healthy adult subjects", "effective_dosage": "Dolutegravir 50 mg once daily; boceprevir 800 mg every 8 h; telaprevir 750 mg every 8 h", "study_duration": "15 days (5 days for Period 1, 10 days for Period 2)", "interactions": "Coadministration of dolutegravir with boceprevir or telaprevir showed no clinically significant pharmacokinetic interactions.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:48.617016+00:00"}
{"study_id": 105109, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it focuses on the protective effects of luteolin against ethanol-induced hepatic steatosis and liver injury.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Male C57BL/6 mice (6 weeks old)", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:49.530232+00:00"}
{"study_id": 105108, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to investigate the off-treatment durability of entecavir therapy in Asian HBeAg-negative chronic hepatitis B patients and the role of HBsAg levels in predicting relapse.", "results_summary": "The study found high rates of virologic relapse (74.2% at 24 weeks, 91.4% at 48 weeks) after stopping entecavir, with no HBsAg clearance observed. Elevated alanine aminotransferase levels occurred in 25.8% of patients during relapse, but HBsAg levels did not correlate with relapse.", "population_specificity": "Asian HBeAg-negative chronic hepatitis B patients (mean age 53.9 years, 67.9% male).", "effective_dosage": "Not specified", "study_duration": "\u2265 2 years of treatment before cessation, followed by 48 weeks of monitoring.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:52.510095+00:00"}
{"study_id": 105110, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the hepatic-protective effects of exenatide versus intensive insulin therapy on alanine aminotransferase (ALT) levels in patients with obesity, NAFLD, and type 2 diabetes.", "results_summary": "Exenatide treatment significantly reduced ALT, AST, and \u03b3GGT levels compared to intensive insulin therapy, and correlated with weight loss and higher fatty liver reversal rates.", "population_specificity": "60 newly diagnosed patients with obesity, NAFLD (elevated liver enzymes), and type 2 diabetes.", "effective_dosage": "Not specified for alanine (exenatide and insulin dosages not detailed in abstract).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.120586+00:00"}
{"study_id": 105111, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers evaluated hydroxychloroquine (HCQ) as an autophagy inhibitor in pancreatic cancer patients and analyzed pharmacodynamic markers, including alanine aminotransferase levels as a safety measure.", "results_summary": "The study found that HCQ monotherapy resulted in inconsistent autophagy inhibition and negligible therapeutic efficacy, with one case of elevated alanine aminotransferase reported as a treatment-related adverse event.", "population_specificity": "Patients with previously treated metastatic pancreatic cancer.", "effective_dosage": "400 mg or 600 mg twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.836038+00:00"}
{"study_id": 105112, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare adverse effects, including changes in alanine transaminase (ALT) levels, in children treated with typical, atypical, or no antipsychotics.", "results_summary": "The study found no significant differences in elevated ALT levels among children treated with typical, atypical, or no antipsychotics. Biochemical parameters, including ALT, remained largely unchanged across treatment groups.", "population_specificity": "72 children (65 boys, 7 girls) aged 6-13 years with various psychopathologies.", "effective_dosage": "Not specified", "study_duration": "At least 4 weeks (control group) or until hospital release (study group)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:56.577545+00:00"}
{"study_id": 105113, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop risk scores for mortality and cirrhosis-related complications in patients with chronic HCV infection and advanced fibrosis, incorporating clinical parameters including alanine aminotransferase levels.", "results_summary": "The study found that the log10 aspartate aminotransferase/alanine aminotransferase ratio was independently associated with mortality (HR=1.30, p=0.001), and the derived risk scores accurately predicted 5-year mortality rates in both derivation and validation cohorts.", "population_specificity": "Patients with chronic HCV infection and advanced fibrosis or cirrhosis.", "effective_dosage": "Not available", "study_duration": "Median follow-up of 8.1 years (derivation cohort) and 6.6 years (validation cohort).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:57.060311+00:00"}
{"study_id": 105114, "supplement_id": 863, "safety_score": "90", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety, tolerability, and efficacy of Aramchol (a fatty acid-bile acid conjugate) in reducing liver fat content and improving metabolic markers in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Aramchol at 300 mg/day significantly reduced liver fat content compared to placebo, with a dose-response relationship observed. The treatment was safe and well-tolerated, with no serious or drug-related adverse events reported, though improvements in metabolic markers were nonsignificant.", "population_specificity": "Patients with biopsy-confirmed NAFLD (including 6 with nonalcoholic steatohepatitis) at 10 centers in Israel.", "effective_dosage": "100 mg or 300 mg once daily.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:57.677263+00:00"}
{"study_id": 105115, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the efficacy and safety of duloxetine and fluoxetine in children and adolescents with major depressive disorder, not specifically Alanine.", "results_summary": "The study did not focus on Alanine's effects but noted that one duloxetine patient experienced elevated alanine aminotransferase (ALT) levels, which resolved during the study.", "population_specificity": "Children (7-11 years) and adolescents (12-17 years) with major depressive disorder.", "effective_dosage": "Not applicable (study focused on duloxetine and fluoxetine, not Alanine).", "study_duration": "36 weeks (10-week acute treatment, 26-week extension).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:57.732489+00:00"}
{"study_id": 105116, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to validate a tracer bolus injection method for measuring glutamine production and assess the impact of alanine and alanyl-glutamine supplementation on glutamine kinetics in healthy volunteers.", "results_summary": "The study found that extra alanine alone did not significantly alter glutamine production compared to the post-absorptive state, suggesting alanine's limited role in modulating glutamine kinetics. Parenteral nutrition with alanyl-glutamine increased glutamine production, but this effect was not attributed to the alanine component.", "population_specificity": "Healthy volunteers in the post-absorptive state", "effective_dosage": "Not specified", "study_duration": "Blood samples collected over 90 minutes post-injection", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:58.706844+00:00"}
{"study_id": 105117, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers reviewed dosimetric brachytherapy audits, including the use of alanine, to assess current practices and propose future directions for improving patient safety and treatment optimization.", "results_summary": "The abstract mentions alanine as one of several approaches used in dosimetric brachytherapy audits but does not provide specific findings about its effects. The study highlights the challenges of dose measurement in brachytherapy and the need for audits to keep pace with advancements in the field.", "population_specificity": "Not specified (focus is on brachytherapy dosimetric audits, not a human or animal population).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.983262+00:00"}
{"study_id": 105118, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 65, "study_goal": "The researchers aimed to determine if rosuvastatin could ameliorate NASH in patients with metabolic syndrome and dyslipidaemia, with secondary observations on alanine transaminase (ALT) levels.", "results_summary": "Rosuvastatin treatment resulted in complete resolution of NASH in 5 out of 6 patients, with significant reductions in ALT (76%) and AST (61%) levels. Lipid values normalized, and liver ultrasonography confirmed NASH resolution in most patients.", "population_specificity": "Patients with metabolic syndrome, NASH confirmed by liver biopsy, and dyslipidaemia (excluding diabetes or arterial hypertension).", "effective_dosage": "10 mg/day", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:01.433406+00:00"}
{"study_id": 105119, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe the role of alanine-glyoxylate aminotransferase deficiency in primary hyperoxaluria type I and evaluate diagnostic and treatment approaches.", "results_summary": "The study found that alanine-glyoxylate aminotransferase deficiency leads to excessive oxalate production, causing kidney damage and oxalosis. Treatment options include conservative management, dialysis (ineffective), and liver or combined liver-kidney transplantation.", "population_specificity": "Patients with primary hyperoxaluria type I, particularly those with kidney damage or on hemodialysis.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:02.400710+00:00"}
{"study_id": 105120, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to examine the prediction of gestational diabetes in obese women using biomarkers, including alanine transaminase, among other clinical measures.", "results_summary": "The study found that plasma adiponectin, not alanine transaminase, was independently associated with gestational diabetes in obese women. Alanine transaminase was measured but did not remain significant in adjusted models.", "population_specificity": "Obese pregnant women (15\u207a\u2070-17\u207a\u2076 weeks' gestation)", "effective_dosage": "Not specified", "study_duration": "Not specified (single measurement at recruitment)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:04.722690+00:00"}
{"study_id": 105123, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effect of switching to Raltegravir on alanine aminotransferase (ALT) levels and other markers in HIV/HCV co-infected individuals.", "results_summary": "The study found a sustained improvement in ALT levels after switching to Raltegravir, with significant decreases at 1 and 6 months post-switch. Hepatitis C viral load also decreased significantly 6 months after the switch.", "population_specificity": "HIV/HCV co-infected individuals na\u00efve to HCV therapy.", "effective_dosage": "Not specified", "study_duration": "6 months post-switch", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:05.439201+00:00"}
{"study_id": 105122, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether inhibition of 11\u03b2-HSD1 by RO5093151 could safely and effectively reduce liver-fat content in patients with non-alcoholic fatty liver disease.", "results_summary": "RO5093151 significantly reduced liver-fat content compared to placebo (p=0.02), but adverse events, including gastrointestinal and nervous system disorders, were more frequent in the treatment group. All serious adverse events were deemed unrelated to the treatment.", "population_specificity": "Adults aged 35-65 with non-alcoholic fatty liver disease, insulin resistance, and BMI >27 kg/m\u00b2.", "effective_dosage": "200 mg twice daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:05.720083+00:00"}
{"study_id": 105121, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify host immune profiles associated with different outcomes (viral rebound vs. HBeAg seroconversion) following treatment withdrawal in chronic hepatitis B patients, focusing on alanine aminotransferase (ALT) flares and cytokine responses.", "results_summary": "Elevated levels of IFN-\u03b3, IP-10, and IL-2 during treatment were linked to HBeAg seroconversion post-withdrawal, while low IFN-\u03b3 levels correlated with viral rebound and ALT flares. Treatment interruption induced distinct immune responses (IFN-\u03b3 vs. IL-10 production) depending on baseline cytokine profiles.", "population_specificity": "Eighteen HBeAg(+) chronic hepatitis B patients enrolled in a phase III trial with adefovir dipivoxil.", "effective_dosage": "Not specified", "study_duration": "Up to 128 weeks (48 weeks continuous therapy, followed by intermittent interruptions)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:06.732824+00:00"}
{"study_id": 105124, "supplement_id": 863, "safety_score": "75", "efficacy_score": 45, "quality_score": 65, "study_goal": "The researchers aimed to assess the beneficial and harmful effects of aminoadamantanes (including amantadine) for patients with chronic hepatitis C infection through a systematic review and meta-analysis of randomized clinical trials.", "results_summary": "The study found no significant effects of amantadine on all-cause mortality, liver-related morbidity, or adverse events. However, in a subgroup analysis, amantadine combined with interferon-alpha and ribavirin showed a modest increase in sustained virological response and normalization of alanine aminotransferase (ALT) levels.", "population_specificity": "Patients with chronic hepatitis C infection (6,193 participants across 41 trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median trial duration was 12 months, with a median follow-up of six months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:07.821785+00:00"}
{"study_id": 105125, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether ischemic preconditioning (IP) could protect the liver against ischemic reperfusion injury after hepatectomy under portal triad clamping (PTC), particularly in patients with liver cirrhosis.", "results_summary": "The study found no statistically significant differences in postoperative liver function tests (including alanine aminotransferase levels), morbidity, mortality, or hospitalization duration between the IP and control groups, concluding that IP did not improve liver tolerance to IR injury.", "population_specificity": "100 patients undergoing hepatectomy with PTC, including 67 with liver cirrhosis.", "effective_dosage": "Not specified", "study_duration": "Postoperative follow-up at days 1, 3, and 7.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:09.539746+00:00"}
{"study_id": 105126, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe the clinical presentation, laboratory characteristics, and outcomes of neonates with disseminated HSV infection, including the role of elevated alanine aminotransferase levels as a diagnostic marker.", "results_summary": "Elevated alanine aminotransferase levels were observed in most but not all neonates with disseminated HSV infection, suggesting it may be a useful but inconsistent diagnostic marker. The study primarily focused on HSV infection outcomes rather than alanine's effects.", "population_specificity": "Neonates (1-14 days old) with disseminated HSV infection confirmed by PCR or viral culture.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:10.565939+00:00"}
{"study_id": 105128, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationship between serum biochemical markers (including alanine aminotransferase, ALT), HCV RNA titers, and the degree of liver damage in chronic HCV patients.", "results_summary": "The study found that ALT levels were significantly correlated with liver fibrosis stages and inflammatory grades in genotype 3a HCV patients, suggesting ALT may serve as a marker for liver damage progression.", "population_specificity": "79 chronic HCV patients (out of 100 enrolled) who underwent liver biopsies.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:12.457439+00:00"}
{"study_id": 105127, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the short-term and long-term efficacy of entecavir versus lamivudine in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure (ACLF), focusing on survival rates, HBV DNA reduction, and ALT levels.", "results_summary": "Entecavir showed faster virological suppression and greater reductions in CTP and MELD scores compared to lamivudine at day 60, but no significant survival improvement. However, at week 52, entecavir significantly improved long-term survival rates (64.6% vs. 48.1%).", "population_specificity": "Hospitalized patients with severe acute exacerbation of chronic hepatitis B presenting as ACLF.", "effective_dosage": "Entecavir 0.5 mg/d or lamivudine 100 mg/d.", "study_duration": "52 weeks (with primary endpoint at day 60).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:13.368197+00:00"}
{"study_id": 105130, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify clinical and diagnostic features of vertebral osteomyelitis, including predictors like elevated alanine transaminase, for differential diagnosis and treatment.", "results_summary": "Elevated alanine transaminase was identified as a predictor of brucellar vertebral osteomyelitis (BVO), but the study did not assess alanine's direct effects or efficacy.", "population_specificity": "214 patients with vertebral osteomyelitis (96 BVO, 63 TVO, 55 PVO) in Ankara, Turkey.", "effective_dosage": "Not available", "study_duration": "Patients were followed for 6 months to 3 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:14.893468+00:00"}
{"study_id": 105131, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to investigate the effect of pentoxifylline on biochemical and histological parameters in patients with nonalcoholic fatty liver disease (NAFLD), including its impact on alanine transaminase activity.", "results_summary": "Pentoxifylline significantly reduced serum alanine transaminase activity and improved histological parameters (steatosis, lobular inflammation, fibrosis) in NAFLD patients, along with reductions in BMI and fasting glucose, but did not significantly affect tumor necrosis factor \u03b1 or adiponectin levels.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:15.322073+00:00"}
{"study_id": 105129, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the recommended dosage for CDDP-TAI plus S-1 combination therapy for advanced hepatocellular carcinoma (HCC), including the safety and efficacy of the treatment.", "results_summary": "The study found that CDDP-TAI plus S-1 was safe, with dose-limiting toxicity not observed at any level. The recommended dosage was 65 mg/m\u00b2 CDDP and 80 mg/m\u00b2 S-1, achieving a disease control rate of 58% (7/12 patients).", "population_specificity": "Twelve Child-Pugh class A or B patients with advanced HCC.", "effective_dosage": "65 mg/m\u00b2 CDDP (infusion, day 1) plus S-1 at 50, 60, or 80 mg/m\u00b2/day (oral administration, days 1-21) every 5 weeks.", "study_duration": "Median of 2 courses per patient (range: 1-6 courses).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:15.371619+00:00"}
{"study_id": 105132, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify predictors of response to PEG-IFN therapy in chronic hepatitis B patients, including the role of pre-treatment alanine aminotransferase levels.", "results_summary": "The study found that high pre-treatment alanine aminotransferase levels, along with other viral and host factors, predict better response to PEG-IFN therapy in HBeAg-positive patients. Early termination of therapy was suggested for non-responders based on Hepatitis B surface antigen stopping rules.", "population_specificity": "Chronic hepatitis B patients, specifically HBeAg-positive and HBeAg-negative individuals, with a focus on Asian and Caucasian populations.", "effective_dosage": "Not specified", "study_duration": "Therapy could be terminated early at week 12 or 24 for non-responders.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.191320+00:00"}
{"study_id": 105133, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether VSL#3 (a gut microbiota modifier) could improve non-alcoholic fatty liver disease (NAFLD) in obese children, with a focus on changes in alanine transaminase (ALT) levels as a secondary outcome.", "results_summary": "The study found that VSL#3 significantly improved NAFLD severity compared to placebo, with no between-group differences in ALT levels. BMI decreased and GLP-1 levels increased in the VSL#3 group, suggesting metabolic benefits.", "population_specificity": "Obese children with biopsy-proven NAFLD.", "effective_dosage": "Not specified in the abstract.", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.996610+00:00"}
{"study_id": 105134, "supplement_id": 863, "safety_score": "30", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to assess the long-term safety and efficacy of eprotirome (a liver-selective thyroid hormone receptor agonist) in lowering LDL cholesterol in patients with familial hypercholesterolaemia.", "results_summary": "Eprotirome significantly lowered LDL cholesterol concentrations but was associated with liver injury markers (elevated AST, ALT, conjugated bilirubin) and was terminated early due to cartilage damage concerns in dogs.", "population_specificity": "Patients aged 18+ with heterozygous familial hypercholesterolaemia not reaching LDL cholesterol targets despite statin therapy with or without ezetimibe.", "effective_dosage": "50 \u03bcg and 100 \u03bcg eprotirome.", "study_duration": "6 weeks (planned for 52-76 weeks but terminated early).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:20.172537+00:00"}
{"study_id": 105135, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify demographic, clinical, and oncologic factors associated with elevated AFP levels in patients with hepatocellular carcinoma (HCC), including the role of alanine aminotransferase levels.", "results_summary": "Elevated alanine aminotransferase levels were independently associated with higher AFP levels in HCC patients, suggesting a link between liver damage and AFP elevation. The study did not assess alanine's direct effects or efficacy as a supplement.", "population_specificity": "4,123 patients with hepatocellular carcinoma managed by the Italian Liver Cancer Group.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:21.568586+00:00"}
{"study_id": 105136, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether antiviral therapy (Peg-IFN plus ribavirin) reduces hepatocellular carcinoma (HCC) incidence in hepatitis C virus (HCV) patients with normal alanine aminotransferase (ALT) levels.", "results_summary": "The study found that sustained virological response (SVR) or relapse significantly reduced HCC incidence compared to nonresponse (NR) in HCV patients with normal ALT levels. Older age and male gender were identified as additional risk factors for HCC.", "population_specificity": "809 patients with HCV infection and normal alanine aminotransferase levels (ALT \u2264 40 IU/mL).", "effective_dosage": "Not specified", "study_duration": "Mean observation period of 36.2 \u00b1 16.5 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:22.649179+00:00"}
{"study_id": 105137, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and clinical outcomes of telbivudine (LdT) versus entecavir (ETV) in patients with chronic hepatitis B and compensated cirrhosis, focusing on alanine aminotransferase normalization and other markers.", "results_summary": "LdT showed lower HBV DNA undetectability (71.6%) and higher resistance rates (23.9%) compared to ETV after 2 years, though clinical outcomes like disease progression and mortality were similar between the two treatments.", "population_specificity": "Chronic hepatitis B patients with compensated cirrhosis.", "effective_dosage": "Not specified", "study_duration": "At least 2 years or less if resistance developed.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:23.904534+00:00"}
{"study_id": 105138, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Caveolin-1 (Cav-1) in protecting hepatocytes from ethanol-mediated nitrosative injury, not specifically Alanine.", "results_summary": "The study found that Cav-1 deficiency worsened ethanol-induced liver damage, while Cav-1 overexpression protected hepatocytes by inhibiting iNOS activity and regulating EGFR/STAT3/iNOS-signaling cascades. Alanine aminotransferase levels were higher in Cav-1 deficient mice, indicating liver damage, but the study did not focus on Alanine's effects.", "population_specificity": "Ethanol-fed mice and human binge drinkers.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Peak effects observed at 12 hours post-ethanol exposure.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:24.964224+00:00"}
{"study_id": 105139, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 60, "study_goal": "The researchers aimed to assess the benefits and harms of nitazoxanide (not Alanine) in people with chronic hepatitis C virus infection.", "results_summary": "Nitazoxanide showed potential in reducing failure to achieve sustained virological response and virological end-of-treatment response, but evidence on clinically relevant outcomes (e.g., mortality, morbidity) was very low quality or absent. No improvement in alanine aminotransferase and aspartate aminotransferase serum levels was observed.", "population_specificity": "Adults (18+ years) with chronic hepatitis C genotype 1 or 4 infection.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.197604+00:00"}
{"study_id": 105140, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the limitations of current biomarkers for drug-induced liver injury (DILI), including alanine aminotransferase, and explore the potential of microRNAs as more specific and sensitive alternatives.", "results_summary": "The abstract highlights that alanine aminotransferase is not liver-specific, leading to false-positive signals, and discusses the promise of microRNAs as biomarkers for DILI, though their release mechanisms and clinical measurement methods remain understudied.", "population_specificity": "Not specified (review of existing research)", "effective_dosage": "Not available", "study_duration": "Not applicable (review study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:26.352928+00:00"}
{"study_id": 105141, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were evaluating the safety and efficacy of combining bevacizumab and temsirolimus in pediatric patients with refractory CNS tumors, not specifically studying alanine.", "results_summary": "The study reported one case of alanine aminotransferase elevation as a grade 3 toxicity, but the focus was on tumor response and drug combination effects, not alanine itself.", "population_specificity": "Pediatric patients (ages 3-14) with chemorefractory CNS tumors (glioblastoma multiforme, medulloblastoma, pontine glioma, ependymoma).", "effective_dosage": "Not applicable (alanine was not a studied intervention).", "study_duration": "Until disease progression or patient withdrawal (specific duration varied by patient).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:27.568949+00:00"}
{"study_id": 105143, "supplement_id": 863, "safety_score": "30", "efficacy_score": null, "quality_score": 60, "study_goal": "The researchers aimed to investigate a case of probable drug-induced liver injury (DILI) attributed to aliskiren, an antihypertensive agent, and assess its hepatotoxicity.", "results_summary": "The study found that aliskiren use was associated with asymptomatic acute hepatic cytolysis, evidenced by elevated liver enzymes (AST, ALT, GGT, ALP), which normalized after discontinuation. Pharmacovigilance data also identified multiple reports of suspected aliskiren hepatotoxicity, including liver failure and deaths.", "population_specificity": "A 61-year-old woman on long-term antiepileptic therapy.", "effective_dosage": "150 mg/day", "study_duration": "Approximately one month", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:29.754207+00:00"}
{"study_id": 105142, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the efficacy of a triple therapy regimen (boceprevir, pegInterferon, and ribavirin) in genotype-1 HCV-infected patients with cirrhosis and bridging fibrosis, focusing on predictors of early virological response, including alanine aminotransferase values.", "results_summary": "The study found that alanine aminotransferase values were an independent predictor of HCV RNA levels at week 12 of therapy, with higher values correlating with poorer response. A stopping score incorporating alanine aminotransferase, hemoglobin levels, and viral load drop showed good predictive utility (AUROC 0.84).", "population_specificity": "Treatment-experienced genotype-1 HCV-infected patients with cirrhosis or bridging fibrosis (mean age 52.6 years, 33.5% with cirrhosis).", "effective_dosage": "Not specified", "study_duration": "12 weeks (primary endpoint measurement)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:29.847610+00:00"}
{"study_id": 105145, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients aged 18-55 years with relapsing-remitting multiple sclerosis.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:30.526521+00:00"}
{"study_id": 105144, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the tolerance of hepatic ischemia/reperfusion injury induced by intermittent hepatic inflow occlusion (IHIO) between livers with macrosteatosis (MaS) and microsteatosis (MiS).", "results_summary": "The study found that MaS significantly increased postoperative transaminase concentrations and biliary complication rates when IHIO exceeded 30 minutes, while MiS had no significant impact. The authors concluded that MaS livers are less tolerant to IR injury than MiS livers and recommended limiting IHIO to \u226430 minutes for MaS donors.", "population_specificity": "144 living liver donors undergoing right hepatectomy, grouped by presence of MaS or MiS.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:31.268925+00:00"}
{"study_id": 105146, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize China's experience with hepatitis A vaccines, including safety, immunogenicity, efficacy, and adverse events after immunization (AEFIs).", "results_summary": "The study found that live and inactivated hepatitis A vaccines in China were immunogenic, effective, and safe, with low rates of adverse events. Live vaccine showed horizontal transmission due to virus shedding, warranting further safety monitoring.", "population_specificity": "Vaccine recipients in China (general population, not specific to Alanine).", "effective_dosage": "Not specified (study focuses on vaccine types, not Alanine dosage).", "study_duration": "Not specified (study reviews postmarketing surveillance and clinical trials without explicit duration).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.166367+00:00"}
{"study_id": 105147, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate short-term outcomes and risk factors for adverse outcomes (liver-related death, transplantation, or chronic liver injury) in patients with drug-induced liver injury (DILI).", "results_summary": "High serum levels of alanine aminotransferase at presentation were identified as an independent risk factor for reduced time to liver-related death or transplantation. The study did not assess alanine as a supplement but rather as a biomarker of liver injury.", "population_specificity": "660 adults with definite, highly likely, or probable DILI (median age 51.4 years, 59.5% female).", "effective_dosage": "Not available", "study_duration": "6-month follow-up after DILI onset", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.645563+00:00"}
{"study_id": 105148, "supplement_id": 863, "safety_score": "30", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers evaluated the safety and efficacy of bosutinib plus letrozole in treating HR+/HER2- breast cancer, with a focus on adverse events including alanine aminotransferase (ALT) elevations.", "results_summary": "The study found significant treatment-related adverse events, including hepatotoxicity (ALT/AST elevations) in 38% of patients. Efficacy was limited, with only one partial response and one case of stable disease.", "population_specificity": "Postmenopausal women with locally advanced or metastatic HR+/HER2- breast cancer.", "effective_dosage": "Bosutinib 400 mg/day plus letrozole 2.5 mg/day.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:34.752515+00:00"}
{"study_id": 105150, "supplement_id": 863, "safety_score": "20", "efficacy_score": 10, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of L-alanine on esophagitis in rats, comparing its impact with other amino acids and identifying potential protective or harmful mechanisms.", "results_summary": "L-alanine had a deleterious effect on esophagitis in rats, worsening the condition, while other amino acids like L-arginine and glycine were protective. The harmful effect of L-alanine was observed alongside the influence of acid/pepsin and prostaglandins in the esophageal injury model.", "population_specificity": "Rats with induced esophagitis", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:38.889646+00:00"}
{"study_id": 105149, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to examine hepatic enzyme levels (including alanine aminotransferase, ALT) in HIV-infected prisoners with opioid or alcohol dependence receiving extended-release naltrexone (XR-NTX) to assess hepatotoxicity concerns.", "results_summary": "The study found no statistically significant differences in ALT levels between participants receiving XR-NTX and placebo, suggesting XR-NTX does not adversely affect hepatic enzymes in this population. The results support the safety of XR-NTX in HIV-infected individuals with high rates of HCV co-infection and mental illness.", "population_specificity": "HIV-infected prisoners transitioning to the community with opioid (44.7%), alcohol (52.9%), or both dependencies (16.5%), and high rates of HCV co-infection (55.7%) and mental illness (39%).", "effective_dosage": "Not specified (once-monthly injectable XR-NTX, but exact dosage not mentioned).", "study_duration": "Not specified (duration of intervention not mentioned in the abstract).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:38.948257+00:00"}
{"study_id": 105153, "supplement_id": 863, "safety_score": "65", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the feasibility and safety of UFT/leucovorin (LV) as adjuvant chemotherapy for patients with resected colorectal liver metastases.", "results_summary": "The study found that UFT/LV had a 54.9% completion rate, with 12.2% experiencing grade 3 or higher adverse events, including elevated alanine aminotransferase levels. Most adverse events were grade 2 or lower and tolerable, suggesting UFT/LV is a safe regimen.", "population_specificity": "Patients who underwent curative resection of liver metastases from colorectal cancer.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:40.675315+00:00"}
{"study_id": 105152, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of ponesimod, an oral selective S1P1 receptor modulator, in treating relapsing-remitting multiple sclerosis (RRMS), with a focus on its impact on new T1 Gd+ lesions and relapse rates.", "results_summary": "Ponesimod significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical endpoints, with the 40 mg dose reducing the annualized relapse rate by 52%. The treatment was generally well tolerated, though some adverse events like increased alanine aminotransferase were more frequent in ponesimod groups.", "population_specificity": "Patients with relapsing-remitting multiple sclerosis (RRMS)", "effective_dosage": "10, 20, or 40 mg once daily", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.147997+00:00"}
{"study_id": 105154, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence and prognostic value of liver function tests, including alanine transaminase (ALT), in patients with acute decompensated heart failure.", "results_summary": "Abnormal ALT levels were found in 12% of patients and were associated with increased 180-day mortality and worsening heart failure. Baseline ALT levels showed significant hazard ratios for adverse outcomes.", "population_specificity": "234 patients with acute decompensated heart failure (mean age 70 \u00b1 10 years, 56% male, 73% NYHA class III/IV).", "effective_dosage": "Not specified", "study_duration": "Measurements taken at baseline and during hospitalization (duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.345298+00:00"}
{"study_id": 105155, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether hepatitis coinfection without hepatic impairment alters lopinavir pharmacokinetics and influences therapy outcomes, including the role of alanine aminotransferase as a cofactor.", "results_summary": "The study found that hepatitis coinfection did not influence lopinavir pharmacokinetics, though lopinavir plasma concentrations were moderately enhanced in coinfected patients. Alanine aminotransferase levels had no significant impact on pharmacokinetic parameters.", "population_specificity": "Patients with HIV alone or coinfected with hepatitis B or C, without clinical signs of hepatic impairment.", "effective_dosage": "Lopinavir/ritonavir 400/100 mg twice daily plus nucleoside reverse transcriptase inhibitors.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.312169+00:00"}
{"study_id": 105151, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether ursodeoxycholic acid (UDCA) treatment upregulates maternal serum and placental CRH expression in patients with intrahepatic cholestasis of pregnancy (ICP).", "results_summary": "UDCA treatment significantly increased maternal serum CRH concentrations and placental CRH expression compared to the control group, alongside reductions in ALT, AST, and TBA levels. The findings suggest UDCA's therapeutic mechanism in ICP may involve CRH upregulation.", "population_specificity": "Pregnant women diagnosed with severe intrahepatic cholestasis of pregnancy (ICP) at 34-34(+6) weeks of gestation.", "effective_dosage": "UDCA 750 mg/d (treatment group); Transmetil 1000 mg/d or Essentiale 1368 mg/d (control group).", "study_duration": "Treatment administered from diagnosis (34-34(+6) weeks) until 37-37(+6) weeks of gestation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.582249+00:00"}
{"study_id": 105156, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare the therapeutic efficacy of entecavir 1mg versus combined lamivudine/adefovir dipivoxil (Lam/Adv) in chronic HBV patients resistant to lamivudine monotherapy, including effects on alanine aminotransferase (ALT) levels.", "results_summary": "Both treatments improved ALT levels equally, but entecavir 1mg achieved better HBV-DNA undetectability earlier. HBeAg seroconversion occurred only in the Lam/Adv group (two cases), while no seroconversion was observed in the entecavir group.", "population_specificity": "Chronic HBV patients resistant to lamivudine monotherapy (25 in Lam/Adv group, 13 in entecavir group).", "effective_dosage": "Entecavir 1mg (group 2); lamivudine 100mg + adefovir dipivoxil (group 1).", "study_duration": "36 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:44.526671+00:00"}
{"study_id": 105157, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of L-citrulline supplementation against a placebo (L-alanine) on splanchnic perfusion, intestinal injury, and barrier function during exercise.", "results_summary": "The study found that L-alanine (placebo) did not prevent splanchnic hypoperfusion or attenuate intestinal injury during exercise, unlike L-citrulline. No significant differences in intestinal permeability were observed between the two treatments.", "population_specificity": "10 male athletes", "effective_dosage": "Not specified (used as placebo)", "study_duration": "Single dose administered pre-exercise", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:46.804640+00:00"}
{"study_id": 105159, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of deferasirox in managing iron overload in pediatric patients with transfusion-dependent \u03b2-thalassemia.", "results_summary": "The treatment was generally well tolerated, with mild to moderate adverse events that reduced over time. Higher doses (\u2265 30 mg/kg per day) effectively reduced iron levels, while lower doses (21-24 mg/kg per day) failed to maintain stable iron balance.", "population_specificity": "87 children aged 2-17 years with transfusion-dependent \u03b2-thalassemia.", "effective_dosage": "9-40 mg/kg per day as a single dose.", "study_duration": "36 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:48.564322+00:00"}
{"study_id": 105161, "supplement_id": 863, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "To determine the safety, pharmacokinetics, and preliminary efficacy of EP-100, a novel anticancer drug linked to a cationic membrane-disrupting peptide, in patients with advanced, LHRH-receptor-expressing solid tumors.", "results_summary": "EP-100 was well tolerated with transient infusion-related dermatologic reactions as the only drug-related adverse event. No complete or partial tumor responses were observed, but seven patients had stable disease for 16 weeks.", "population_specificity": "Patients with advanced, solid tumors positive for LHRH receptor by immunohistochemistry.", "effective_dosage": "0.6-40 mg/m\u00b2, administered weekly or twice weekly.", "study_duration": "3 of 4 weeks per 28-day cycle.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:49.799384+00:00"}
{"study_id": 105160, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of a combination of metformin and carnitine-orotate complex versus metformin alone in improving liver function and glucose metabolism in patients with fatty liver and impaired glucose tolerance.", "results_summary": "The combined treatment significantly reduced ALT levels more than metformin alone, improved oxidative stress markers, and increased mitochondrial DNA copy number, with no severe adverse events reported.", "population_specificity": "Drug-na\u00efve patients with impaired glucose metabolism (fasting glucose 100-240 mg/dL or HbA1c \u2265 6.0%) and fatty liver (ALT 40-250 IU/L).", "effective_dosage": "Metformin (250 mg t.i.d.) and carnitine-orotate complex (300 mg t.i.d.).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:50.048126+00:00"}
{"study_id": 105163, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the tolerability and effectiveness of a combination of S-1 with sorafenib in patients with advanced hepatocellular carcinoma (HCC), not specifically studying Alanine.", "results_summary": "The study found that the combination therapy had a maximum tolerated dose (MTD) of S-1 64 mg/m\u00b2/day and sorafenib 800 mg/day, with common adverse effects including increased alanine aminotransferase (15.4%). The treatment showed modest clinical activity in advanced HCC patients.", "population_specificity": "Patients with advanced hepatocellular carcinoma (HCC).", "effective_dosage": "S-1 64 mg/m\u00b2/day (days 1-14) and sorafenib 800 mg/day (daily), repeated every 21 days.", "study_duration": "Treatment cycles repeated every 21 days; median overall survival was 10.5 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:52.983624+00:00"}
{"study_id": 105162, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of an interferon-free, ribavirin-free all-oral therapy (daclatasvir and asunaprevir) in patients with chronic HCV genotype 1b infection, focusing on sustained virologic response and adverse events.", "results_summary": "The study found that the combination therapy achieved high sustained virologic response rates (87.4% in interferon-ineligible/intolerant patients and 80.5% in nonresponder patients) with a low rate of serious adverse events (5.9%). Common adverse events included increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST), nasopharyngitis, headache, diarrhea, and pyrexia.", "population_specificity": "Patients with chronic HCV genotype 1b infection who were interferon-ineligible/intolerant or nonresponders to prior interferon-based therapy, including those with and without cirrhosis.", "effective_dosage": "Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.835928+00:00"}
{"study_id": 105164, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to determine whether methionine supplementation (compared to alanine as a control) could increase protein-derived cysteine and improve glutathione synthesis in children with edematous severe acute malnutrition (SAM).", "results_summary": "Alanine was used as a control and showed no significant difference in cysteine de novo synthesis, total cysteine flux, or erythrocyte glutathione synthesis rate compared to methionine supplementation. Methionine increased cysteine flux from protein breakdown but did not significantly affect glutathione synthesis.", "population_specificity": "Children with edematous severe acute malnutrition (SAM).", "effective_dosage": "0.5 mmol \u22c5 kg(-1) \u22c5 d(-1) of alanine.", "study_duration": "Administered from clinical phase 1 (3 \u00b1 1 days after admission) to clinical phase 3 (14 \u00b1 2 days after admission).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.923707+00:00"}
{"study_id": 105165, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, efficacy, and impact on liver fibrosis of tenofovir disoproxil fumarate (TDF) in Asian-American patients with chronic hepatitis B (CHB).", "results_summary": "TDF demonstrated high efficacy, with 82% of patients achieving HBV DNA suppression at Week 48, improved alanine aminotransferase levels, and reduced liver fibrosis severity. No resistance to TDF developed, and treatment was well tolerated with mostly mild adverse events.", "population_specificity": "Adult Asian-American patients with chronic hepatitis B from private medical and community-based practices.", "effective_dosage": "300 mg once daily", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:54.887228+00:00"}
{"study_id": 105166, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether entecavir improves liver histology and virological outcomes in chronic hepatitis B patients with persistently normal alanine aminotransferase (PNALT).", "results_summary": "The study found that entecavir achieved significant virological efficacy (76.2% undetectable HBV DNA vs. 0% in placebo) but did not demonstrate histological improvement compared to placebo.", "population_specificity": "Chronic hepatitis B patients with persistently normal alanine aminotransferase (PNALT).", "effective_dosage": "Not specified in the abstract.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.859885+00:00"}
{"study_id": 105168, "supplement_id": 863, "safety_score": "30", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to assess the effects of resveratrol, including its impact on alanine aminotransferase levels, in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Resveratrol administration increased alanine aminotransferase levels, indicating hepatic stress, but did not improve insulin resistance, steatosis, or other NAFLD features. No significant changes in metabolic or antioxidant markers were observed.", "population_specificity": "Overweight or obese men diagnosed with NAFLD.", "effective_dosage": "3000 mg resveratrol daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:57.773109+00:00"}
{"study_id": 105167, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, maximum-tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, a PI3K and mTOR inhibitor, in patients with advanced solid tumors.", "results_summary": "The study found that SAR245409 had a manageable safety profile, with common adverse events including nausea, diarrhea, and vomiting. It demonstrated reduced PI3K and mTOR pathway signaling and was associated with stable disease in 48% of evaluable patients, though no significant tumor regression was observed.", "population_specificity": "Patients with advanced solid tumors.", "effective_dosage": "15-120 mg twice daily and 70-100 mg once daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:57.912971+00:00"}
{"study_id": 105158, "supplement_id": 863, "safety_score": "60", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and efficacy of idelalisib, a PI3K\u03b4 inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL).", "results_summary": "The study found an overall response rate of 40%, with common adverse events including diarrhea, nausea, and elevated liver enzymes (alanine transaminase/aspartate transaminase). Median progression-free survival was 3.7 months, and 1-year PFS was 22%.", "population_specificity": "40 patients with relapsed or refractory mantle cell lymphoma (median age 69, range 52-83).", "effective_dosage": "50-350 mg daily or twice daily.", "study_duration": "Median treatment duration was 3.5 months (range 0.7-30.7).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:59.380956+00:00"}
{"study_id": 105169, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers sought to describe the characteristics of castor bean seed exposures, including symptoms and outcomes, reported to a poison control system.", "results_summary": "The study found that gastrointestinal symptoms (e.g., vomiting, nausea) were most common after castor bean seed exposure, but no serious morbidity, mortality, or delayed symptoms were reported. Laboratory abnormalities were rare, with only one case showing elevated AST/ALT levels.", "population_specificity": "Cases reported to a state-wide poison control system (2001-2011) involving castor bean seed exposure.", "effective_dosage": "Not applicable (exposure varied: median 10 seeds for intentional, 1 seed for unintentional cases).", "study_duration": "Follow-up ranged from 0.5 to 285.5 hours.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:01.587551+00:00"}
{"study_id": 105171, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effects of pentoxifylline therapy on liver function and histological changes in patients with NAFLD/NASH, including its impact on alanine aminotransferase levels.", "results_summary": "Pentoxifylline therapy significantly reduced alanine aminotransferase levels (P < 0.00001) and improved liver function and histological changes, such as NAFLD activity score and lobular inflammation, but did not significantly affect other markers like BMI, cholesterol, or fibrosis.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.181239+00:00"}
{"study_id": 105170, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether fish oil-based parenteral lipid preparation (FOLP) could halt or reverse PN-associated cholestasis (PNAC) compared to soy-based lipid preparation (SLP) and assess its effects on liver function and growth.", "results_summary": "FOLP significantly slowed the progression of PNAC compared to SLP, as indicated by lower rates of increase in plasma-conjugated bilirubin and alanine aminotransferase. Increased enteral nutrition further improved PNAC in infants receiving FOLP.", "population_specificity": "Infants with PNAC (plasma-conjugated bilirubin \u2265 34 \u00b5mol/l) expected to require prolonged parenteral nutrition.", "effective_dosage": "1.5 g/kg/day of either FOLP or SLP.", "study_duration": "Up to 4 months after commencement of lipid treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.958687+00:00"}
{"study_id": 105173, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of peginterferon \u03b1-2a or \u03b1-2b plus ribavirin in treating chronic hepatitis C (CHC) in a diverse population, including patients with comorbidities or special populations (CSP).", "results_summary": "The study found a sustained virological response rate of 56.6% overall, with higher rates in patients without CSP (59.7%) compared to those with CSP (53.1%). Significant predictors of response included HCV genotype, absence of cirrhosis, lower viral load, and prescription of peginterferon \u03b1-2a.", "population_specificity": "Adults with chronic hepatitis C, including those with comorbidities or special populations (CSP) such as cirrhosis, demographic variations, and laboratory abnormalities.", "effective_dosage": "Not specified (investigator's discretion)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:05.167400+00:00"}
{"study_id": 105174, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 65, "study_goal": "The researchers aimed to determine the effect of fructose, including its impact on alanine aminotransferase (ALT), as a marker of non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that fructose in hypercaloric trials increased ALT levels, suggesting a potential link to NAFLD, but no effect was observed in isocaloric trials. The effect may be more attributable to excess energy rather than fructose itself.", "population_specificity": "260 healthy participants", "effective_dosage": "Hypercaloric trials used high-dose fructose (+104-220 g/day).", "study_duration": "\u2264 4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:05.807974+00:00"}
{"study_id": 105176, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare surrogate markers (including alanine aminotransferase) with liver biopsy in assessing liver histology and iron content in children with sickle cell anemia on chronic transfusion therapy.", "results_summary": "The study found no significant correlation between ferritin and alanine aminotransferase or between alanine aminotransferase and liver iron content or fibrosis. Alanine aminotransferase did not serve as a reliable surrogate marker for liver pathology in this context.", "population_specificity": "Children with sickle cell anemia on chronic transfusion and chelation therapy.", "effective_dosage": "Not specified", "study_duration": "Retrospective review over a 9-year period", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:08.260353+00:00"}
{"study_id": 105175, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of the FOLFOX regimen versus fluorouracil and cisplatin in chemoradiotherapy for localized oesophageal cancer, not specifically to evaluate Alanine.", "results_summary": "The study found no significant difference in progression-free survival between the FOLFOX and fluorouracil-cisplatin groups. Adverse events like increased alanine aminotransferase concentrations were more common in the FOLFOX group, but the study did not focus on Alanine's effects.", "population_specificity": "Patients aged 18+ with localized stage I-IVA oesophageal carcinoma (adenocarcinoma, squamous-cell, or adenosquamous), ECOG status 0-2, and adequate organ function.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 25.3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:08.396040+00:00"}
{"study_id": 105177, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to assess the effects of the molecular absorbent recirculating system (MARS) on liver function and recovery in patients with acute liver failure, liver failure with cirrhosis, and cholestatic patients with intractable pruritus.", "results_summary": "MARS significantly improved liver function markers (bilirubin, AST, ALT, GGT, ALP) and encephalopathy grade. In ALF patients, 37% recovered without transplantation after MARS therapy.", "population_specificity": "Mexican patients with acute liver failure (38), liver failure with cirrhosis (15), and cholestatic disease with intractable pruritus (17).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:10.547045+00:00"}
{"study_id": 105178, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the efficacy and safety of sarilumab, an IL-6R\u03b1 blocker, in patients with ankylosing spondylitis, not specifically Alanine.", "results_summary": "The study found no significant efficacy of sarilumab in treating ankylosing spondylitis, though higher doses reduced hs-CRP levels. Safety profile was manageable, with common adverse events including infections, neutropenia, and elevated alanine aminotransferase.", "population_specificity": "Patients with active ankylosing spondylitis despite conventional treatment.", "effective_dosage": "100, 150, or 200 mg every other week, or 100 or 150 mg every week.", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.171589+00:00"}
{"study_id": 105179, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether HBV genotype B or C influences the response to interferon therapy, particularly focusing on outcomes like ALT normalization, HBV DNA negativity, and HBeAg seroconversion.", "results_summary": "The study found that HBV genotype B patients had significantly higher rates of sustained ALT normalization, HBV DNA negativity, HBeAg clearance, and HBeAg seroconversion compared to genotype C patients. The results were consistent across multiple endpoints, though heterogeneity was noted in some analyses.", "population_specificity": "HBeAg-positive chronic hepatitis B patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.348737+00:00"}
{"study_id": 105172, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the long-term efficacy of telbivudine (LdT) in hepatitis B virus (HBV)-related compensated versus decompensated cirrhotic patients over 96 weeks.", "results_summary": "Alanine aminotransferase normalization rates were significantly higher in compensated cirrhotic patients compared to decompensated patients at weeks 12 and 24. The compensated group also showed earlier improvements in albumin levels and liver stiffness, while decompensated patients exhibited delayed but significant improvements.", "population_specificity": "Treatment-naive patients with HBV-related compensated (n=65) or decompensated (n=62) cirrhosis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:13.798464+00:00"}
{"study_id": 105181, "supplement_id": 863, "safety_score": "75", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of ASP9831, a phosphodiesterase-4 inhibitor, in altering serum alanine aminotransferase (ALT) levels and other biomarkers in patients with NASH.", "results_summary": "ASP9831 did not significantly change serum ALT or AST levels or other NASH biomarkers compared to placebo after 12 weeks. Most adverse events were mild, with gastrointestinal disorders more frequent in the ASP9831 groups.", "population_specificity": "Patients with nonalcoholic steatohepatitis (NASH).", "effective_dosage": "50 mg or 100 mg twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:13.861682+00:00"}
{"study_id": 105180, "supplement_id": 863, "safety_score": "80", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, and efficacy of tideglusib, a GSK-3 inhibitor, in treating progressive supranuclear palsy (PSP), with a focus on its effects on alanine aminotransferase levels.", "results_summary": "The study found no significant differences in primary or secondary endpoints between tideglusib and placebo. Tideglusib was generally safe but caused asymptomatic, transient alanine aminotransferase elevations in 9% of patients and diarrhea in 13%.", "population_specificity": "146 patients with mild-to-moderate progressive supranuclear palsy (PSP).", "effective_dosage": "600 mg or 800 mg once daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:15.022582+00:00"}
{"study_id": 105183, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess whether modified ALT criteria (males <30, females <19 IU/L) better associate with disease phases in Asian Americans with chronic hepatitis B (CHB) compared to conventional ALT criteria.", "results_summary": "The modified ALT criteria reclassified 28.1% of patients, with 72.1% moving to more active CHB phases, and identified higher rates of fibrosis and inflammation. It was more sensitive than conventional criteria in detecting active CHB phases.", "population_specificity": "Asian Americans with chronic hepatitis B (198 non-treated patients).", "effective_dosage": "Not specified", "study_duration": "Mean follow-up of 21 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:17.365200+00:00"}
{"study_id": 105182, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to determine if pioglitazone (PIO) could improve treatment response in HIV/HCV genotype 1-coinfected patients with insulin resistance who previously did not respond to peginterferon/ribavirin (PegIFN/RBV).", "results_summary": "The study found that only 15.8% of subjects achieved undetectable HCV RNA after combined PegIFN/RBV/PIO treatment, which was not significantly different from the historical null rate of 10%. However, alanine aminotransferase and aspartate aminotransferase levels declined significantly during PIO monotherapy, correlating with improved metabolic parameters.", "population_specificity": "Adult HIV/HCV genotype 1-coinfected patients with insulin resistance (homeostatic model assessment >2.5) who were previous nonresponders to PegIFN/RBV.", "effective_dosage": "Not specified for alanine (study focused on pioglitazone).", "study_duration": "24 weeks of PIO monotherapy followed by PegIFN/RBV/PIO combination therapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.827250+00:00"}
{"study_id": 105186, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the role of antioxidant vitamins, including their dietary intake, plasma levels, and supplementation effects, in obese children and adolescents with nonalcoholic fatty liver disease, with a focus on markers like alanine aminotransferase.", "results_summary": "The study found that vitamin supplementation improved disease progression markers such as alanine aminotransferase levels and histological features, though improvements were not statistically significant in all studies. Lifestyle changes, including dietary adjustments and increased physical activity, showed more consistent benefits.", "population_specificity": "Obese children and adolescents with nonalcoholic fatty liver disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:20.084567+00:00"}
{"study_id": 105184, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to determine whether dipeptidyl peptidase-4 inhibition (which affects peptides with alanine) potentiates vasodilator and fibrinolytic responses to substance P when ACE is inhibited.", "results_summary": "The study found that sitagliptin (a dipeptidyl peptidase-4 inhibitor) did not significantly affect vasodilator responses to substance P or bradykinin but increased heart rate and norepinephrine release during combined ACE and dipeptidyl peptidase-4 inhibition. In women, sitagliptin reduced tissue plasminogen activator release in response to substance P.", "population_specificity": "Twelve healthy subjects", "effective_dosage": "Sitagliptin 200 mg orally", "study_duration": "Single-day intervention", "interactions": "Combined effects with ACE inhibitor (enalaprilat) noted", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:20.142405+00:00"}
{"study_id": 105185, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers compared risk factors, clinical presentation, and disease progression in patients hospitalized with H7N9, H5N1, and pH1N1 virus infections, including elevated alanine aminotransferase levels as a marker of liver injury.", "results_summary": "H7N9 patients exhibited elevated alanine aminotransferase levels similar to H5N1 patients, both significantly different from pH1N1 patients, indicating liver involvement in severe cases. The study did not focus on alanine as a supplement but rather as a biomarker of disease severity.", "population_specificity": "Hospitalized patients with H7N9 (n=123), H5N1 (n=119), and pH1N1 (n=3486) virus infections.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:21.266364+00:00"}
{"study_id": 105188, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare patient characteristics and outcomes after transarterial chemoembolization for hepatocellular carcinoma (HCC) based on viral etiology (HBV, HCV, both, or none).", "results_summary": "The study found no significant difference in overall survival among the different hepatitis groups. Patients with HBV had lower alanine aminotransferase levels and higher albumin levels compared to HCV patients.", "population_specificity": "201 patients with unresectable HCC undergoing first-time transarterial chemoembolization.", "effective_dosage": "Not available", "study_duration": "Median follow-up of 28.3 months \u00b1 16.2", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:21.444907+00:00"}
{"study_id": 105187, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of tocilizumab add-on versus switch strategies in adults with active rheumatoid arthritis despite methotrexate treatment, not specifically focused on Alanine.", "results_summary": "The study found that both tocilizumab strategies led to meaningful clinical and radiographic responses, with some endpoints favoring the add-on strategy. Alanine aminotransferase elevations >3\u00d7 upper limit of normal were observed in 11% of add-on and 3% of switch patients with normal baseline values.", "population_specificity": "Adults with active rheumatoid arthritis despite methotrexate treatment.", "effective_dosage": "Tocilizumab 8 mg/kg every 4 weeks.", "study_duration": "1 year (52 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:22.723861+00:00"}
{"study_id": 105190, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it examines the safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Adults aged 18-55 years with relapsing multiple sclerosis.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:23.560181+00:00"}
{"study_id": 105189, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 76, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the effects of single and combination antiviral therapies (TDF and TDF+emtricitabine) on HBeAg-positive chronic hepatitis B patients with high viral loads and normal alanine aminotransferase levels.", "results_summary": "The combination of TDF and emtricitabine provided better viral suppression (76% achieved HBV DNA <69 IU/mL) compared to TDF alone (55%), though HBeAg seroconversion and hepatitis B surface antigen loss rates were low. Both regimens were well tolerated with no viral resistance observed.", "population_specificity": "HBeAg-positive chronic hepatitis B patients (mean age 33, 89% Asian) with high HBV DNA levels and normal alanine aminotransferase, predominantly infected with HBV genotypes B and C.", "effective_dosage": "TDF (300 mg daily) and emtricitabine (200 mg daily).", "study_duration": "192 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:24.947427+00:00"}
{"study_id": 105191, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of topiroxostat in hyperuricemic stage 3 chronic kidney disease patients with or without gout.", "results_summary": "Topiroxostat significantly reduced serum urate levels and urinary albumin-to-creatinine ratio compared to placebo, though it had a higher incidence of increased alanine aminotransferase. Serious adverse event rates were similar between groups.", "population_specificity": "Hyperuricemic stage 3 chronic kidney disease patients with or without gout.", "effective_dosage": "160 mg/day", "study_duration": "22 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.277160+00:00"}
{"study_id": 105194, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it evaluates daclatasvir and asunaprevir for HCV treatment in genotype 1 null responders.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Non-cirrhotic genotype 1 HCV null responders.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.986606+00:00"}
{"study_id": 105193, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to identify factors influencing the outcome of hepatitis C virus (HCV) genotype 4 exposure, including the role of alanine aminotransferase (ALT) levels in predicting spontaneous viral clearance.", "results_summary": "A rapid decline in ALT (>300 IU/l within 4 weeks) was independently associated with spontaneous HCV clearance, and ALT normalization predicted sustained virologic response (SVR) in treated patients.", "population_specificity": "Subjects recently exposed to HCV genotype 4, including those with acute HCV and exposed but apparently uninfected participants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:28.780016+00:00"}
{"study_id": 105192, "supplement_id": 863, "safety_score": "30", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers evaluated the safety of AZD7762 (a Chk1 kinase inhibitor) monotherapy and in combination with gemcitabine, including its effects on alanine aminotransferase levels.", "results_summary": "The study found that alanine aminotransferase/aspartate aminotransferase increases occurred in 26% of patients, indicating potential liver-related adverse effects. Cardiac toxicity was also noted, leading to discontinuation of AZD7762 development.", "population_specificity": "Advanced solid tumor patients.", "effective_dosage": "AZD7762 doses ranged from 6 mg to 40 mg, administered intravenously on days 1 and 8 of a 14-day run-in cycle (monotherapy) and then combined with gemcitabine (750-1,000 mg/m\u00b2) every 21 days.", "study_duration": "The study included a 14-day run-in cycle (monotherapy) followed by combination therapy cycles every 21 days (duration not explicitly stated beyond this).", "interactions": "Gemcitabine did not affect AZD7762 pharmacokinetics.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:31.299681+00:00"}
{"study_id": 105195, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effect of peginterferon (PEG-IFN) on intrahepatic hepatitis B core and surface antigen (HBcAg and HBsAg) expression in chronic hepatitis B (CHB) patients and its relation to therapy response.", "results_summary": "PEG-IFN therapy significantly reduced intrahepatic HBsAg expression in HBeAg-negative CHB patients and showed a trend in HBeAg-positive patients. Loss of intrahepatic HBsAg post-treatment predicted a sustained response and was associated with a pronounced decline in serum HBsAg levels.", "population_specificity": "HBeAg-positive (n=52) and HBeAg-negative (n=67) chronic hepatitis B (CHB) patients.", "effective_dosage": "Not specified", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:31.434603+00:00"}
{"study_id": 105197, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to investigate the safety and efficacy of tolcapone, including its effects on liver enzymes like alanine aminotransferase, under routine practice conditions in patients with Parkinson's disease.", "results_summary": "The study found that tolcapone was generally safe, with rare but notable increases in liver enzymes (including alanine aminotransferase), most of which normalized without intervention. Efficacy was demonstrated through physician-reported improvements in clinical global impression for a majority of patients.", "population_specificity": "Patients with Parkinson's disease.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:32.778673+00:00"}
{"study_id": 105198, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of etanercept and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and mild hepatitis C virus (HCV) infection, not specifically Alanine.", "results_summary": "The study found no significant changes in AST, ALT, or HCV viral load across treatment arms, with significant reductions in DAS44 and HAQ scores at 54 weeks. No patients discontinued due to worsening liver disease.", "population_specificity": "Patients with active RA and mild HCV infection (n=29).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Up to 54 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:33.539102+00:00"}
{"study_id": 105199, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the correlation between serum IP-10 levels and liver inflammation markers (including alanine aminotransferase, ALT) in chronic hepatitis B patients undergoing Peg IFN-\u03b1 therapy.", "results_summary": "Higher pre-treatment IP-10 levels and their dynamic reduction during therapy were associated with better treatment outcomes (HBeAg clearance and HBsAg decline). IP-10 levels correlated positively with ALT and hepatic inflammation but negatively with HBV DNA load and HBsAg levels.", "population_specificity": "Chronic asymptomatic HBV carriers, chronic hepatitis B patients, and HBV-related acute-on-chronic liver failure patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.425391+00:00"}
{"study_id": 105200, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare liver graft outcomes between LDLT recipients receiving small-for-size grafts (aGRWR < 0.8%) and those receiving larger grafts (aGRWR \u2265 0.8%).", "results_summary": "The study found that recipients with smaller grafts (aGRWR < 0.8%) had comparable graft survival rates to those with larger grafts, though small-for-size syndrome (SFSS) was more frequent in the smaller graft group. Alanine aminotransferase levels were higher in the smaller graft group post-transplant, but not significantly.", "population_specificity": "Patients undergoing living donor liver transplantation (LDLT) with right lobe liver grafts.", "effective_dosage": "Not specified", "study_duration": "Evaluated within 4 weeks post-transplantation, with long-term follow-up (1-, 3-, and 5-year survival rates).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.539079+00:00"}
{"study_id": 105201, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the end treatment response (ETR) and sustained viral response (SVR) of interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 3 patients, including the role of serum alanine aminotransferase levels.", "results_summary": "The study found that 74.1% of patients achieved ETR, while 98% achieved SVR. Serum alanine aminotransferase levels were approximately twice the upper normal limit in patients who achieved ETR and SVR.", "population_specificity": "Pakistani patients with chronic hepatitis C genotype 3 infections, excluding those with decompensated liver disease or co-infections (hepatitis B or HIV).", "effective_dosage": "Interferon alpha, 3 million international units (MIU), subcutaneously 3 times weekly, and ribavirin >800 mg/d.", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:38.999153+00:00"}
{"study_id": 105204, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were not studying Alanine; the abstract focuses on everolimus and its effects on hepatocellular carcinoma (HCC).", "results_summary": "The abstract does not discuss Alanine; it summarizes the antitumor effects and adverse events of everolimus in HCC and solid cancers.", "population_specificity": "Patients with solid cancers and hepatocellular carcinoma (HCC) who received liver transplantation.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned (Alanine not studied).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:40.130888+00:00"}
{"study_id": 105202, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC), not specifically Alanine.", "results_summary": "The study found that nintedanib in combination with docetaxel improved progression-free survival and overall survival in patients with adenocarcinoma histology, but did not focus on Alanine.", "population_specificity": "Patients with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy.", "effective_dosage": "Not applicable (study did not focus on Alanine).", "study_duration": "Until unacceptable adverse events or disease progression (median follow-up of 7.1 months for PFS, 31.7 months for overall survival).", "interactions": "None mentioned (study did not focus on Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:40.228508+00:00"}
{"study_id": 105203, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of tenofovir disoproxil fumarate (TDF) on reducing HBV transmission in highly viremic mothers during late pregnancy, with a secondary focus on alanine aminotransferase normalization.", "results_summary": "TDF therapy significantly reduced perinatal HBV transmission (0% vs. 8.3% in controls) and led to higher rates of HBV DNA suppression (<250 copies/mL) and normalized alanine aminotransferase levels (82% vs. 61%) in mothers. No adverse events or congenital deformities were observed in mothers or infants.", "population_specificity": "Pregnant patients with hepatitis B e antigen (+) chronic hepatitis B and HBV DNA levels > 10\u2077 copies/mL.", "effective_dosage": "TDF 300 mg/d", "study_duration": "From week 18 to 27 of gestation", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:41.183979+00:00"}
{"study_id": 105205, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of synbiotic supplementation on hepatic fibrosis, liver enzymes (including alanine aminotransferase, ALT), and inflammatory markers in patients with NAFLD.", "results_summary": "Synbiotic supplementation significantly reduced ALT levels and other liver enzymes, inflammatory markers, and fibrosis scores compared to placebo, indicating improved liver health in NAFLD patients. The effects were statistically significant and clinically meaningful.", "population_specificity": "52 patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Twice daily supplementation (exact dosage not specified).", "study_duration": "28 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:41.525869+00:00"}
{"study_id": 105206, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical applications of the ESR/alanine dosimetry system in radiotherapy, focusing on its properties and potential improvements for new modalities like intensity-modulated radiation therapy and radiosurgery.", "results_summary": "The study found that alanine/ESR dosimetry meets key requirements for clinical applications, including water-equivalent composition, energy independence, and high precision. Improvements in sensitivity and minidosimeter development expanded its use in advanced radiotherapy and low-dose detection.", "population_specificity": "Not specified (focused on clinical applications in radiotherapy, not a specific human population).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.097831+00:00"}
{"study_id": 105196, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the safety and recommended dosage of combination chemotherapy with sorafenib and transcatheter arterial infusion (TAI) using cisplatin for advanced hepatocellular carcinoma (HCC) patients.", "results_summary": "The study found dose-limiting toxicities and adverse events, including elevated alanine aminotransferase (20%). Partial response was seen in 20% of patients, and 65% had stable disease. The recommended regimen was sorafenib at 800 mg/day with TAI of cisplatin at 65 mg/m\u00b2/cycle.", "population_specificity": "Patients with advanced hepatocellular carcinoma (HCC) not eligible for surgical resection, local ablation therapy, or transcatheter arterial chemoembolization.", "effective_dosage": "Cisplatin at 35 mg/m\u00b2, 50 mg/m\u00b2, or 65 mg/m\u00b2 per cycle; sorafenib at 800 mg daily.", "study_duration": "Up to six cycles, repeated every 4-6 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.157684+00:00"}
{"study_id": 105207, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it examines the efficacy and safety of sofosbuvir-containing regimens for chronic hepatitis C.", "results_summary": "The study does not report findings on Alanine.", "population_specificity": "Patients with chronic hepatitis C (genotypes 1, 2, and 3).", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not mentioned for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.333809+00:00"}
{"study_id": 105208, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the proportion of chronic hepatitis B (CHB) patients with alanine transaminase (ALT) levels \u2264 40 IU/L who had significant liver fibrosis (stage \u2265 2).", "results_summary": "Approximately 20.7% of CHB patients with ALT \u2264 40 IU/L had significant fibrosis, regardless of HBeAg status, high HBV DNA levels, ethnicity, or age. This proportion increased to 27.8% when using stricter ALT upper limits (30 IU/L for males, 19 IU/L for females).", "population_specificity": "Chronic hepatitis B (CHB) patients with ALT levels \u2264 40 IU/L, including subgroups by HBeAg status, HBV DNA levels, Asian ethnicity, and age.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:48.282421+00:00"}
{"study_id": 105209, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the efficacy of Vitamin B6 in reducing urinary oxalate excretion in patients with Primary Hyperoxaluria type I (PH I), a condition linked to AGT enzyme deficiency involving alanine metabolism.", "results_summary": "The study found a mean relative reduction in urinary oxalate excretion of 25.5%, with 50% of patients achieving a \u226530% reduction. No complete biochemical remission was observed, even in homozygous Gly170Arg participants.", "population_specificity": "12 patients (7 male) with genetically confirmed PH I and noncompromised renal function.", "effective_dosage": "5 mg/kg body weight per day, increased by 5 mg/kg every 6 weeks up to 20 mg/kg per day.", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:49.739432+00:00"}
{"study_id": 105210, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to evaluate whether an optimized treatment strategy (adding adefovir for suboptimal responders) improved clinical outcomes in HBeAg-positive chronic hepatitis B patients compared to telbivudine monotherapy.", "results_summary": "The optimized strategy (telbivudine plus adefovir for suboptimal responders) resulted in higher rates of HBV DNA suppression (76.7% vs. 61.2%) and lower genotypic resistance (2.7% vs. 25.8%) compared to monotherapy, with comparable HBeAg seroconversion and ALT normalization rates. Both regimens were well tolerated, with no increased side effects.", "population_specificity": "HBeAg-positive, nucleos(t)ide-naive chronic hepatitis B patients (n=606).", "effective_dosage": "Telbivudine monotherapy or telbivudine plus adefovir (specific dosages not mentioned).", "study_duration": "104 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:50.162747+00:00"}
{"study_id": 105212, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects and mechanism of Active Hexose Correlated Compound (AHCC) supplementation on liver enzyme levels and inflammatory markers in patients with alcohol-induced mildly elevated liver enzymes.", "results_summary": "AHCC supplementation significantly reduced ALT levels, lowered pro-inflammatory cytokines (TNF-\u03b1 and IL-1\u03b2), and increased anti-inflammatory adiponectin compared to placebo. The effects were consistent across both 1 g and 3 g AHCC doses.", "population_specificity": "Patients with alcohol-induced mildly elevated liver enzyme levels.", "effective_dosage": "1 g AHCC and 3 g AHCC daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:50.912716+00:00"}
{"study_id": 105214, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "To evaluate the long-term efficacy and safety of mipomersen (which affects alanine aminotransferase levels) in patients with familial hypercholesterolaemia.", "results_summary": "Mipomersen provided sustained reductions in LDL-C, apolipoprotein B, and other lipoproteins over 104 weeks. Safety profile was consistent with prior trials, with adverse events like injection site reactions and transient increases in liver fat.", "population_specificity": "Patients with familial hypercholesterolaemia on maximally tolerated lipid-lowering therapy (n = 141).", "effective_dosage": "200 mg subcutaneous injection weekly.", "study_duration": "Up to 104 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:52.707229+00:00"}
{"study_id": 105213, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 45, "study_goal": "The researchers aimed to assess the effects of statins (including their impact on alanine aminotransferase levels) on mortality, adverse events, and biochemical responses in patients with NAFLD or NASH.", "results_summary": "The study found no statistically significant improvement in aminotransferase levels with statins compared to placebo or other treatments. Liver histology was unaffected, and no data on mortality were reported.", "population_specificity": "Patients with NAFLD or NASH.", "effective_dosage": "Simvastatin 40 mg daily; atorvastatin 20 mg daily.", "study_duration": "12 months (simvastatin trial); 54 weeks (atorvastatin trial).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:52.811088+00:00"}
{"study_id": 105215, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the proportion of chronic hepatitis B (CHB) patients with slightly elevated ALT levels who also had significant liver fibrosis (stage \u22652).", "results_summary": "The study found that 48% of CHB patients with ALT levels 1- to 2-fold the upper limit of normal had significant fibrosis, with similar rates in hepatitis B e antigen-positive and negative subgroups. The findings suggest that modest ALT elevations may still indicate advanced liver disease, warranting individualized treatment thresholds.", "population_specificity": "Treatment-naive chronic hepatitis B (CHB) patients with ALT levels 1- to 2-fold the upper limit of normal and histologic data.", "effective_dosage": "Not specified", "study_duration": "6 months or more of follow-up evaluation", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.322131+00:00"}
{"study_id": 105211, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the association between baseline HOMA-IR (a marker for insulin resistance) and sustained virologic response (SVR) to telaprevir-based therapy in genotype 1 hepatitis C patients with prior peginterferon/ribavirin treatment failure.", "results_summary": "Baseline HOMA-IR was associated with SVR in univariate analysis but not in multivariate analysis, suggesting other factors have a more direct causal relationship with virologic response to telaprevir-based therapy than HOMA-IR. Alanine aminotransferase/aspartate aminotransferase levels were associated with higher baseline HOMA-IR.", "population_specificity": "Genotype 1 hepatitis C patients with prior peginterferon/ribavirin treatment failure.", "effective_dosage": "Telaprevir (750 mg q8h), peginterferon (180 \u03bcg/week), ribavirin (1,000-1,200 mg/day).", "study_duration": "12 weeks of telaprevir plus peginterferon/ribavirin, followed by peginterferon/ribavirin alone for 48 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.354911+00:00"}
{"study_id": 105218, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential pathogenetic relationship between mitochondrial dysfunction (including abnormal alanine levels) and autism spectrum disorder (ASD).", "results_summary": "The study found elevated alanine levels in patients with ASD, suggesting abnormal mitochondrial metabolic function, and identified genetic and biochemical evidence linking mitochondrial dysfunction to ASD in a subset of children.", "population_specificity": "Children with autism spectrum disorder (ASD) and mitochondrial disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:57.011996+00:00"}
{"study_id": 105216, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to examine the effect of antioxidant supplementation (including Alanine) on biomarkers of oxidative stress, inflammation, and liver function in obese children.", "results_summary": "Antioxidant supplementation improved antioxidant-oxidant balance and modestly improved liver function tests (specifically alanine aminotransferase), but did not reduce markers of systemic inflammation.", "population_specificity": "Overweight or obese children and adolescents (n = 44; mean age 12.7 \u00b1 1.5 years).", "effective_dosage": "Not specified for Alanine (study included vitamin E, vitamin C, and selenium).", "study_duration": "4 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:57.319254+00:00"}
{"study_id": 105217, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers assessed the safety and tolerability of bosutinib in patients with chronic-phase or advanced Philadelphia chromosome-positive leukemia, not specifically Alanine.", "results_summary": "The study found that bosutinib had manageable toxicities, primarily gastrointestinal adverse events and myelosuppression, with successful rechallenge in most cases of alanine aminotransferase elevation.", "population_specificity": "Patients with chronic-phase chronic myeloid leukemia or advanced Philadelphia chromosome-positive leukemia resistant/intolerant to imatinib and possibly other TKIs.", "effective_dosage": "500 mg per day (bosutinib, not Alanine).", "study_duration": "Median duration was 11.1 months (range, 0.03-83.4 months).", "interactions": "None mentioned (for Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:59.232323+00:00"}
{"study_id": 105220, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the durability of virological response in chronic hepatitis B patients with lamivudine-resistant HBV after switching to adefovir monotherapy versus maintaining lamivudine-adefovir combination therapy.", "results_summary": "The study found that 94.4% of patients who switched to adefovir monotherapy maintained HBV DNA suppression for 96 weeks, compared to 100% in the combination therapy group. Two patients in the monotherapy group experienced virological rebound but regained suppression after switching back to combination therapy.", "population_specificity": "Chronic hepatitis B patients with lamivudine-resistant HBV and undetectable viral loads after at least 6 months of lamivudine-adefovir combination therapy.", "effective_dosage": "Not specified", "study_duration": "96 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:00.171905+00:00"}
{"study_id": 105224, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate ocular fundus abnormalities in patients with \u03b2-thalassemia and assess risk factors, including alanine amino transferase levels, associated with these abnormalities.", "results_summary": "The study found that increased retinal vascular tortuosity was associated with aspartate amino transferase levels, among other factors, but did not specifically report on alanine's effects.", "population_specificity": "Patients with \u03b2-thalassemia major (TM) and \u03b2-thalassemia intermedia (TI) (n=255).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:01.140658+00:00"}
{"study_id": 105223, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the potential benefits of including alanine in bedtime snacks for preventing nocturnal hypoglycemia in individuals with type 1 diabetes.", "results_summary": "Some evidence suggests that alanine in bedtime snacks may provide benefits for preventing nocturnal hypoglycemia, but the overall level of evidence is low and not conclusive for patients using insulin analogues.", "population_specificity": "Individuals with type 1 diabetes, particularly those at high risk for nocturnal hypoglycemia (e.g., long-standing diabetes, hypoglycemia unawareness, prior physical activity, alcohol consumption, or bedtime blood glucose close to hypoglycemia threshold).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:01.449581+00:00"}
{"study_id": 105221, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to develop a scoring system to predict sustained virological response (SVR) in hepatitis C virus (HCV) genotype 1 patients treated with peginterferon alfa-2a/ribavirin, using baseline characteristics including alanine aminotransferase levels.", "results_summary": "The study devised a scoring system incorporating alanine aminotransferase levels, among other factors, which reliably predicted SVR rates, with higher scores (\u22655) correlating with significantly better outcomes (76.7% SVR). The system was validated in additional patient cohorts, confirming its predictive utility.", "population_specificity": "Treatment-naive Caucasian patients with HCV genotype 1 mono-infection.", "effective_dosage": "Not specified (study focused on baseline characteristics, not dosing).", "study_duration": "Not specified (study analyzed pretreatment predictors, not intervention duration).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.608148+00:00"}
{"study_id": 105222, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify post-treatment risk factors, including alanine aminotransferase levels, for hepatocellular carcinoma (HCC) in chronic HCV patients treated with pegylated interferon plus ribavirin.", "results_summary": "Higher integrated levels of alanine aminotransferase were identified as a post-treatment risk factor for HCC in patients without sustained virologic response (SVR). The study did not focus on alanine's direct effects but noted its association with HCC risk.", "population_specificity": "2659 patients with chronic hepatitis C without a history of HCC, treated in Japan from 2002 to 2008.", "effective_dosage": "Not specified for alanine (study focused on Peg-IFN plus ribavirin).", "study_duration": "48 to 72 weeks for HCV genotype 1, 24 weeks for genotype 2.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.729950+00:00"}
{"study_id": 105225, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy of deferasirox (DFX) in reducing iron overload and improving hematologic and hepatic function in patients with myelodysplastic syndromes (MDS) or aplastic anemia (AA).", "results_summary": "DFX significantly reduced serum ferritin and liver iron concentration levels, improved hemoglobin and platelet counts, and decreased elevated alanine aminotransferase levels in patients with MDS or AA.", "population_specificity": "Chronically transfused patients with myelodysplastic syndromes (MDS) or aplastic anemia (AA) showing serum ferritin levels of at least 1000 ng/mL.", "effective_dosage": "Daily DFX (specific dosage not mentioned in the abstract).", "study_duration": "Up to 1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:05.673947+00:00"}
{"study_id": 105226, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the associations between immunohistochemical staining of hepatitis antigens (HDAg, HBsAg, HBcAg) and liver injury markers, including alanine aminotransferase (ALT), in chronic delta hepatitis (CDH).", "results_summary": "The study found that HDAg staining positively correlated with ALT levels, suggesting an association with liver injury, while HBcAg staining negatively correlated with liver injury. HBsAg staining was linked to HBV replication markers but not directly to liver injury.", "population_specificity": "Patients with chronic delta hepatitis (CDH) from the HIDIT 1 study.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:05.921850+00:00"}
{"study_id": 105227, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the role of DPP4, including its interaction with alanine, in regulating hematopoietically active molecules and its potential to enhance hematopoietic cell transplantation.", "results_summary": "The study found that DPP4 can truncate proteins at the N-terminus residue for alanine and other amino acids, implicating it in regulating hematopoiesis. It suggests modulating DPP4 activity may enhance single-unit cord blood transplantation in adults.", "population_specificity": "Primarily focused on mouse models and clinical settings of single-unit cord blood hematopoietic cell transplantation in adults.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:08.248121+00:00"}
{"study_id": 105228, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to examine the effects of EGCG on body composition, metabolism, cardiometabolic risk factors, and liver function enzymes, including alanine aminotransferase, in obese women after an energy-restricted diet.", "results_summary": "The study found no significant differences in liver function markers, including alanine aminotransferase, between the EGCG and control groups, suggesting EGCG supplementation did not affect these biomarkers.", "population_specificity": "Obese pre-menopausal women (BMI 30-40 kg/m\u00b2)", "effective_dosage": "300 mg/d of EGCG", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:08.725751+00:00"}
{"study_id": 105229, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it investigates the efficacy and safety of ritonavir-boosted danoprevir (DNVr) plus peginterferon alfa-2a-ribavirin in HCV genotype 1-infected prior null responders.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "HCV genotype 1-infected prior peginterferon-ribavirin null responders.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:09.174915+00:00"}
{"study_id": 105232, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the effects of prednisolone or infliximab on urea synthesis regulation in patients with active IBD, using alanine infusion to quantify urea synthesis.", "results_summary": "Prednisolone increased urea synthesis by 40%, exacerbating nitrogen loss, while infliximab reduced it by 15%, suggesting less nitrogen depletion. The difference between treatments was statistically significant.", "population_specificity": "Patients with active inflammatory bowel disease (IBD).", "effective_dosage": "Not specified", "study_duration": "7 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:10.270227+00:00"}
{"study_id": 105230, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the outcomes of transarterial chemoembolization using degradable starch microspheres (DSMs) versus conventional chemoembolization with doxorubicin and Ethiodol in patients with unresectable intermediate-stage hepatocellular carcinoma (HCC).", "results_summary": "The study found no significant differences in mean survival or complication rates between DSM and conventional chemoembolization groups. Tumor response rates were similar, with objective response rates of 44.1% for DSM and 48.6% for conventional chemoembolization.", "population_specificity": "Patients with unresectable intermediate-stage hepatocellular carcinoma (HCC).", "effective_dosage": "50 mg doxorubicin per chemoembolization procedure.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:10.452196+00:00"}
{"study_id": 105231, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a shorter modified acetylcysteine regimen or ondansetron pretreatment could reduce adverse effects (including changes in alanine aminotransferase activity) in paracetamol poisoning treatment.", "results_summary": "The study found that a 12-hour modified acetylcysteine regimen reduced vomiting and anaphylactoid reactions compared to the standard regimen. However, ondansetron pretreatment was associated with a higher proportion of patients showing a 50% increase in alanine aminotransferase activity.", "population_specificity": "Patients with acute paracetamol overdose in three UK hospitals.", "effective_dosage": "Not specified for alanine (study focused on acetylcysteine and ondansetron).", "study_duration": "12-hour modified acetylcysteine regimen vs. 20.25-hour standard regimen.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:12.512540+00:00"}
{"study_id": 105234, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare the immunomodulatory gene expression changes induced by Vytorin (Ezetimibe/Simvastatin) versus Simvastatin monotherapy in hypercholesterolemic subjects.", "results_summary": "Vytorin altered genes related to inflammation/oxidative stress (downregulated NF-KappaB, upregulated IL-10, GPX1, SOD2) and cellular activation/adhesion (upregulated VWF, F7, PF4, etc.), while Simvastatin affected genes linked to apoptosis/proliferation (upregulated APAF1, BAX, etc.). Vytorin also improved lipid profiles and CRP levels more effectively than Simvastatin alone.", "population_specificity": "20 hypercholesterolemic subjects", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:15.039726+00:00"}
{"study_id": 105233, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and adverse effects of statin uptitration versus statin combined with ezetimibe in patients with chronic kidney disease (CKD), focusing on outcomes like muscle complaints and liver enzyme elevations.", "results_summary": "The study found that combination therapy with ezetimibe resulted in fewer adverse effects (e.g., myalgia, elevated liver enzymes) compared to statin uptitration, particularly in advanced CKD stages. No serious adverse effects like rhabdomyolysis were observed, and LDL cholesterol reductions were similar between groups.", "population_specificity": "Patients with CKD (stages 3-5) whose LDL cholesterol remained above 120 mg/dl despite statin therapy.", "effective_dosage": "Ezetimibe 10 mg daily added to usual statin dose.", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:15.283536+00:00"}
{"study_id": 105235, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to review the clinical applications of enzymes, including alanine transaminase, in disease diagnosis and monitoring.", "results_summary": "The abstract highlights that enzymes like alanine transaminase are valuable markers for diagnosing and assessing diseases such as myocardial infarction, jaundice, and cancer, but does not provide specific results on alanine's efficacy.", "population_specificity": "Not specified (general clinical applications)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:15.669537+00:00"}
{"study_id": 105236, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to develop guidelines for managing hepatitis B virus (HBV) reactivation risk in rheumatic disease patients undergoing immunosuppressive therapy, including monitoring alanine aminotransferase levels.", "results_summary": "The study recommends screening for HBV markers and monitoring alanine aminotransferase and HBV DNA levels in patients with resolved HBV infection during immunosuppressive therapy to detect reactivation early and initiate nucleoside analog treatment if needed.", "population_specificity": "Patients with rheumatic diseases commencing immunosuppressive therapy, particularly in HBV-endemic regions like Japan.", "effective_dosage": "Not specified", "study_duration": "Monitoring recommended during and at least 12 months after withdrawal of immunosuppressive therapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:18.051615+00:00"}
{"study_id": 105237, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were examining the role of alanine aminotransferase monitoring in hepatitis B reactivation risk among IBD patients undergoing immunosuppressive therapy.", "results_summary": "The study highlights the importance of monitoring alanine aminotransferase and hepatitis B virus DNA in HBsAg-negative, anti-HBc-positive IBD patients post-immunosuppressive therapy to detect viral reactivation. Alanine aminotransferase serves as a biomarker for liver injury in these cases.", "population_specificity": "Patients with inflammatory bowel disease (IBD) undergoing immunosuppressive therapy, particularly those at risk for hepatitis B reactivation.", "effective_dosage": "Not specified", "study_duration": "Monitoring recommended within 12 months after the end of immunosuppressive therapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:19.508472+00:00"}
{"study_id": 105240, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy of lamivudine plus adefovir versus entecavir for treating lamivudine-resistant chronic hepatitis B (CHB).", "results_summary": "The study found no significant differences in undetectable HBV DNA levels, alanine aminotransferase normalization, HBeAg loss, or HBeAg seroconversion between the two treatment groups. However, virologic breakthrough was higher in the entecavir group compared to the lamivudine plus adefovir group.", "population_specificity": "Patients with lamivudine-resistant chronic hepatitis B (CHB).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:20.726162+00:00"}
{"study_id": 105239, "supplement_id": 863, "safety_score": "65", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and efficacy of the mTOR inhibitor temsirolimus (TEM) in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with recurrent/refractory solid tumors, including CNS tumors.", "results_summary": "The study identified dose-limiting toxicities, including elevated serum alanine aminotransferase and triglycerides, but the combination therapy was generally well-tolerated at the maximum tolerated dose (MTD). Six patients showed objective responses, with three sustaining responses through \u226514 cycles.", "population_specificity": "Pediatric patients (median age 10.9 years, range 1.0-21.5) with recurrent/refractory solid tumors, including neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, CNS tumors, and others.", "effective_dosage": "TEM 35 mg/m\u00b2 IV weekly, IRN 90 mg/m\u00b2 PO days 1-5, TMZ 125 mg/m\u00b2 PO days 1-5 every 21 days.", "study_duration": "Cycles of 21 days, with some patients receiving \u226514 cycles.", "interactions": "Dose-limiting hyperlipidemia occurred in patients receiving oral corticosteroids; chronic steroid use was precluded after protocol amendment.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:22.791790+00:00"}
{"study_id": 105238, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the degree of weight reduction needed to improve hepatic function and insulin resistance markers, including Alanine Aminotransferase (ALT), in type-2 diabetics with NAFLD.", "results_summary": "The study found a 40.8% reduction in ALT levels in the intervention group, along with improvements in other liver enzymes and insulin resistance markers, following a 15% reduction in BMI through aerobic exercise and diet.", "population_specificity": "Type-2 diabetic male patients with NAFLD (n=100, divided into two groups).", "effective_dosage": "Not specified (intervention involved aerobic exercise and diet regimen).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:37.553115+00:00"}
